

# Single-session anodal transcranial direct current stimulation to enhance sport-specific performance in athletes: A systematic review and meta-analysis

Tom Maudrich, Patrick Ragert, S. Perrey, Rouven Kenville

# ▶ To cite this version:

Tom Maudrich, Patrick Ragert, S. Perrey, Rouven Kenville. Single-session anodal transcranial direct current stimulation to enhance sport-specific performance in athletes: A systematic review and meta-analysis. Brain Stimulation, 2022, 15 (6), pp.1517 - 1529. 10.1016/j.brs.2022.11.007 . hal-04180969

# HAL Id: hal-04180969 https://hal.science/hal-04180969

Submitted on 14 Aug 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. Brain Stimulation 15 (2022) 1517-1529

Contents lists available at ScienceDirect

# **Brain Stimulation**

journal homepage: http://www.journals.elsevier.com/brain-stimulation

# Single-session anodal transcranial direct current stimulation to enhance sport-specific performance in athletes: A systematic review and meta-analysis



霐

BRAIN

Tom Maudrich <sup>a, b, \*</sup>, Patrick Ragert <sup>a, b</sup>, Stéphane Perrey <sup>c</sup>, Rouven Kenville <sup>a, b</sup>

<sup>a</sup> Department of Movement Neuroscience, Faculty of Sport Science, Leipzig University, Leipzig, Germany

<sup>b</sup> Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany

<sup>c</sup> EuroMov Digital Health in Motion, Univ Montpellier, IMT Mines Ales, Montpellier, France

# ARTICLE INFO

Article history: Received 23 June 2022 Received in revised form 13 October 2022 Accepted 22 November 2022 Available online 26 November 2022

Keywords: Anodal transcranial direct current stimulation Athletes Sport-specific performance Meta-analysis Systematic review

#### ABSTRACT

*Background:* Transcranial direct current stimulation (tDCS) has emerged as a promising and feasible method to improve motor performance in healthy and clinical populations. However, the potential of tDCS to enhance sport-specific motor performance in athletes remains elusive.

*Objective:* We aimed at analyzing the acute effects of a single anodal tDCS session on sport-specific motor performance changes in athletes compared to sham.

*Methods:* A systematic review and meta-analysis was conducted in the electronic databases PubMed, Web of Science, and SPORTDiscus. The meta-analysis was performed using an inverse variance method and a random-effects model. Additionally, two subgroup analyses were conducted (1) depending on the stimulated brain areas (primary motor cortex (M1), temporal cortex (TC), prefrontal cortex (PFC), cerebellum (CB)), and (2) studies clustered in subgroups according to different sports performance domains (endurance, strength, visuomotor skill).

*Results:* A total number of 19 studies enrolling a sample size of 258 athletes were deemed eligible for inclusion. Across all included studies, a significant moderate standardized mean difference (SMD) favoring anodal tDCS to enhance sport-specific motor performance could be observed. Subgroup analysis depending on cortical target areas of tDCS indicated a significant moderate SMD in favor of anodal tDCS compared to sham for M1 stimulation.

*Conclusion:* A single anodal tDCS session can lead to performance enhancement in athletes in sportspecific motor tasks. Although no definitive conclusions can be drawn regarding the modes of action as a function of performance domain or stimulation site, these results imply intriguing possibilities concerning sports performance enhancement through anodal M1 stimulation.

© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY licenses (http://creativecommons.org/licenses/by/4.0/).

#### 1. Introduction

Top athletic performance arises from optimal integration of physical and mental capacities, both of which can be trained and improved through appropriate interventions. At the core of such interventions, especially in the physical domain, often lies the refinement of neural information processing, i.e., facilitation of sensory input, filtering of relevant stimuli, and streamlining motor responses [1]. In addition to traditional physical training, non-

\* Corresponding author. Department of Movement Neuroscience, Faculty of Sport Science, Leipzig University, Leipzig, Germany.

invasive brain stimulation (NIBS) has emerged as a potential performance-enhancing tool over the past decades [2]. Although a number of NIBS techniques have been developed to modulate cortical processing, transcranial direct current stimulation (tDCS) is one of the more promising and feasible strategies to enhance athletic performance [3]. This is due to the low risk associated with the method, the simplicity of implementation, lack of interference during task execution, and comparably low costs [2]. tDCS involves the application of a subthreshold current to the brain, which in general, depending on the polarity (anodal or cathodal stimulation), leads to an increase (anodal) or decrease (cathodal) in the excitability of the cortical areas underneath the stimulation electrode [4]. However, some studies report a threshold for stimulation

https://doi.org/10.1016/j.brs.2022.11.007

1935-861X/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).



E-mail address: tom.maudrich@uni-leipzig.de (T. Maudrich).

intensity and duration at which a reversal of cortical excitability can be observed, i.e., anodal stimulation decreases excitability and cathodal stimulation increases excitability [5–8]. While the aforementioned findings focused on local excitability changes underneath the stimulation electrode, recent evidence suggests that the spatial resolution of tDCS is more differentiated due to a sophisticated pattern of electric field distribution in the brain depending on the individual anatomical and geometric properties of the head [9], electrode montages used as well as shape and type of the electrodes [10,11]. tDCS has been successfully employed in healthy and clinical populations. Both cognitive and motor functions could be improved in healthy adults, and partially restored in patients suffering from Parkinson's disease or stroke (for a detailed description of these findings, please see the following reviews [12–15]).

The fact that tDCS has been reported to be a potential performance-enhancing tool in several domains has focused attention on enhancing physical performance in sports (please see the following opinion articles for further reading [16,17]). Particularly in the context of motor functions, there is a growing interest to evaluate the potential of tDCS in high-performance populations, i.e., athletes. This is evident, among other things, in the recent increase in reviews and meta-analyses evaluating the enhancement of motor skills by tDCS in healthy individuals (for further reading please refer to Refs. [18-20]). Initial positive findings led to the now-common term *Neurodoping* [16]. Interestingly, many of such findings related to increases in motor and cognitive functions in healthy, fit, but not athletically active individuals. Hence, evidence for tDCS-induced performance enhancement among athlete groups remains elusive. Currently, only a limited number of studies have evaluated tDCS-induced performance enhancements in athletes. Results are mixed, with some studies showing improvements in a variety of physical performance measures [21,22] while others did not find significant changes [23] or even deterioration [24]. A critical aspect of studies on performance enhancement of athletes using brain stimulation is the choice of motor task. Many studies aimed to increase general conditional abilities, i.e., strength and endurance through tDCS [25,26]. Others investigated the effects of tDCS on abstracted motor tasks, e.g., serial reaction time tasks or finger tapping tasks [27]. However, few studies have investigated whether or not tDCS is capable of improving sport-specific motor performance in athletes. Oftentimes, controlled, stationary motor tasks unrelated to the specific need in a sports discipline, were investigated in laboratory settings, e.g., visually cued reaction times in football and handball athletes [28]. To truly investigate tDCS effects on performance enhancement in athletes, ideally, motor tasks should be studied that have a high overlap with the sport of the investigated athletes. First, this increases the likelihood of performance improvement of an already high-level athlete since positive motor transfer, i.e., the degree to which motor performance in one task can be transferred to another task, is related to task-related experience [29-31]. On the other hand, such sportspecific tasks are more valuable because they relate to the athlete's sport and therefore have higher relevance to the sport than tasks that test general motor skills.

As noted above, reviews and meta-analyses already exist that highlight the potential of tDCS to enhance performance in the motor domain [18–20]. However, none of these studies have focused on sport task specificity in athletes. Therefore, the present work aims to address this question, by conducting a systematic review and meta-analysis of studies that investigated acute effects of anodal tDCS on sport-specific performance changes in athletes. The predominant use of anodal stimulation for motor performance enhancement is based on empirical evidence, i.e., several reviews and meta-analyses show an effect of anodal stimulation on motor performance enhancement whereas comparable effects of cathodal stimulation have yet to be demonstrated [19,20,32]. The positive charge imposed by anodal tDCS is hypothesized to cause a depolarization of the resting membrane potential of neurons, inferring that the effect of anodal tDCS would be mediated by changes in neural excitability [4]. Hence one reason for using anodal tDCS over the motor regions would be to increase excitability of these regions which could result in a sustained neural drive of the motor neurons, to the active muscles and, therefore, improved muscle output. The present work, therefore, focuses on studies using anodal stimulation to enhance sport-specific performance. Although on a cellular level, the relationship between tDCS-induced excitability changes and global performance gains still remains elusive, current literature is striving to unravel the underlying mechanisms. The interested reader is referred to Refs. [33,34].

Here, the term sport-specific motor tasks denote such tasks that have a high overlap with motor tasks in the sport of the investigated athlete groups. Peak athletic performance is highly specific. In this sense, the investigation of sport-specific performance changes through tDCS seems essential to further approach the understanding of the potential of tDCS applications under real-life conditions compared to highly controlled laboratory settings. Such evidence might also have relevance in the context of neuromodulation in neurorehabilitation or prevention.

#### 2. Materials and methods

The systematic review and meta-analysis were conducted following the guidelines and recommendations contained in the PRISMA 2020 statement [35] and according to Cochrane guidelines [36].

# 2.1. Eligibility criteria

Studies were deemed eligible for analysis according to the PICOS inclusion criteria [37] if they contained the following factors:

- Population: healthy male or female adult athletes (participating regularly in organized sport for at least 2 years before the experiment), free of injury or neural disease
- Intervention: acute effects of a single anodal tDCS session on sport-specific motor performance
- Comparator: sham stimulation in a single or double-blind design
- Outcomes: performance in sport-specific motor tasks
- Study design: randomized-controlled trials (RCT) with crossover or parallel design

Articles that did not meet the inclusion criteria were excluded from this systematic review and meta-analysis.

#### 2.2. Information sources

A systematic literature search was performed by two independent researchers (TM, RK) in the electronic databases PubMed, Web of Science, and SPORTDiscus with publication year until August 2022. The reference lists of the included studies were also scanned to generate a broader scope of the search. Only studies published in the English language were reviewed and included in the systematic review and meta-analysis.

#### 2.3. Search strategy

Searches were performed in PubMed (all fields), Web of Science (all fields), and SPORTDiscus (all fields) using the keywords "transcranial direct current stimulation" OR "tDCS" AND "athletes".

# 2.4. Selection process

Records were screened and selected by two review authors (TM, RK) independently based on previously defined PICOS eligibility

criteria (see flow diagram Fig. 1). Disagreements were resolved by reaching a consensus or by involving a third person (PR).

# 2.5. Data extraction

Two review authors (TM, RK) independently extracted the following data items from the included studies:

- 1. Methods: study design (crossover/parallel RCT).
- 2. Participants: number, gender, sports discipline, training experience




Fig. 1. PRISMA flow chart diagram depicting the study selection process. Initially, 251 records were identified of which 19 studies were deemed eligible within the scope of the qualitative and quantitative synthesis.

- 3. tDCS application: tDCS electrode location, stimulation intensity, stimulation density, stimulation duration, motor task during/ after stimulation, high-definition (HD)-tDCS or conventional tDCS.
- 4. Outcomes: sport-specific motor tasks.
- 5. Notes: funding for studies and notable conflicts of interest of authors.

Disagreements were resolved by reaching a consensus or by involving a third person (PR). If data were not reported within a manuscript, the authors of the original papers were contacted or values were extracted using Webplot Digitizer version 4.4 (https://apps.automeris.io/wpd/).

#### 2.6. Risk of bias assessment

Risk of bias assessment for randomized trials was performed by two review authors (TM, RK) independently according to the criteria contained in the Cochrane guidelines [38]: (1) random sequence generation (selection bias) (2) allocation concealment (selection bias), (3) blinding of participants and personnel (performance bias), (4) blinding of outcome assessment (detection bias), (5) incomplete outcome data (attrition bias), (6) selective reporting (reporting bias), and (7) "other bias." For every included study, each of these items was classified as "low risk of bias" ("+"), "high risk of bias" ("-"), or "unclear risk of bias" ("?"). For this purpose, the software Review Manager 5.4.1 (Cochrane Collaboration, Oxford, UK) was used. Any disagreements in ratings of risk of bias were handled by a conversation between the two evaluators and consultation with a third person (PR).

#### 2.7. Quantitative analysis

The meta-analysis was performed using Review Manager 5.4.1 (Cochrane Collaboration, Oxford, UK). The intervention effects of tDCS on sport-specific motor performance changes were calculated within each study using the standardized mean difference (SMD) of the continuous data at a 95% confidence interval (95%CI). Therefore, the mean difference and standard deviation in performance between anodal tDCS and sham were calculated in a sport-specific motor task closely related to competition in the sports discipline (e.g., cycling -20 min time trial on a bicycle ergometer). In the case of multiple motor tasks performed within one study, the motor task that best represents competition performance in the respective athlete population was selected (for selected sport-specific tasks, please see Table 1). For tasks in which reaction times or time trials were assessed, mean outcome values were multiplied by -1 to ensure that all intervention effects pointed in the same direction (i.e., lower reaction time means better performance). Because the included studies used different sport-specific motor tasks in various populations of trained individuals, SMDs were weighted by the inverse variance method, and a random-effects model was used to account for statistical heterogeneity and to minimize the imprecision of the pooled effect estimate. Studies were clustered in subgroups depending on the brain area stimulated by tDCS (i.e., primary motor cortex (M1), temporal cortex (TC), prefrontal cortex (PFC), cerebellum (CB)). Furthermore, a separate meta-analysis was conducted with studies clustered in subgroups according to different sports performance domains (i.e., endurance, strength, visuomotor skill). Here, studies were divided into these groups depending on the most prominent performance domain in each respective sport studied (e.g., cycling - endurance; bodybuilding strength; pistol-shooting - visuomotor skill) [19]. According to Cochrane guidelines, pooled standardized mean differences of subgroup analyses and the overall effect were estimated using Cohen's effect size: small ( $\leq 0.2$ ), moderate ( $\leq 0.5$ ) large ( $\leq 0.8$ ), and very large (> 0.8). The degree of heterogeneity between studies was assessed using Chi<sup>2</sup> (p < 0.1 considered significant) and the  $l^2$  statistic, with values from  $\leq 50\%$  indicating low heterogeneity, 50%–75% moderate heterogeneity, and >75% high level of heterogeneity, and visual inspection of the funnel plot.

# 3. Results

# 3.1. Study selection

The systematic literature search yielded a total of 251 records. After removal of 40 duplicates, 211 records were screened, of which 144 were excluded based on title and abstract. The remaining 67 records were assessed for eligibility. Based on PICOS criteria, 48 records were excluded due to the following reasons: no homogeneous athlete sample (n = 24), no RCT (n = 9), no sport-specific motor task was performed (n = 13), article not in English (n = 1), no single tDCS-Session (n = 1). Finally, a total of 19 studies were deemed eligible for inclusion in the qualitative synthesis [3,23,24,39–54]. An overview of the study selection process is depicted in the PRISMA flow diagram (Fig. 1).

#### 3.2. Risk of bias assessment

The risk of bias was found to be low in most of the studies reviewed. However, 9 of the 19 included studies (47%) were singleblind trials, which poses a risk of detection bias due to problems with blinding of the outcome assessment. A summary of the risk of bias assessment is visualized in Fig. 2.

# 3.3. Study design and participant characteristics

A comprehensive summary of study characteristics is presented in Table 1. All included studies were designed as crossover RCT with sham as a comparator and published between 2015 and 2022. Interestingly, the majority of studies (68%) were published in the last 3 years, highlighting the recent interest in this area of research. In total, 258 trained athletes (mean age range: 19–33 years) were enrolled in these studies, with 203 being male and 55 being female. Sample sizes of included studies ranged from 8 to 36 participants  $(13.6 \pm 6.5)$ . Athletes were experienced in various sports disciplines: cycling [23,39,45,46,51], swimming [47,49,53], triathlon [40], rowing [51,52], bodybuilding [41], resistance training [48], basketball [50], volleyball [54], parkour [3], taekwondo [24,42] and pistol-shooting [43]. Additionally, some studies reported that athletes competed at the regional [49], national [24,42,47,52-54] and/ or international level [24,40,42,47]. For an overview of investigated sport-specific motor performances in each study, please see Table 1. Sport disciplines were categorized in the following performance domains: endurance (cycling [23,39,45,46,51], swimming [47,49,53], triathlon [40], rowing [51,52]), strength (bodybuilding [41], resistance training [48]) & visuomotor skill (basketball [50], volleyball [54], parkour [3], taekwondo [24,42], pistol-shooting [43]).

Only anodal tDCS conditions from experiments in which stimulations with multiple polarities were applied were analyzed in the current systematic review and meta-analysis due to our study aims of investigating performance-enhancing effects. For tDCS application, the following electrode montages were used: conventional tDCS (one pair of sponge electrodes), bilateral conventional tDCS (two pairs of sponge electrodes), Halo-Sport device (headphones with two implemented electrodes), and HD-tDCS (arrays of small gel-based electrodes). Conventional tDCS was used in 10 studies (52%), bilateral conventional tDCS in 4 studies (21%), the Halo-Sport

Table 1				
Overview of studies investigating a	ute anodal tDCS-induce	ed sport-specific p	erformance changes in traine	d athletes.

Study	Design	Participants (F — female, M — male)	Training experience	Anode (A) Cathode (C)	Current intensity (mA)			Sport-specific motor performance	Outcome
Okano et al., 2015	Crossover	10 cyclists (all M)	10—11 years	A – left TC (T3) C – right supraorbital area (Fp2)	2	0.057	20	Peak power output (PPO) on cycle ergometer	a-tDCS improved PPO compared to sham
Holgado et al., 2019	Crossover	36 cyclists (all M)	$Mean \ VO_2max = 54 \ mL\bullet min^{-1} \bullet kg^{-1}$	A – PFC (F3) C – right shoulder	2	0.08	20	20 min time trial (TT) on cycle ergometer	No significant difference between a-tDCS and sham
Kamali, Nami et al., 2019	Crossover	8 pistol-shooters (4 F, 4 M)	2–3 years pistol-shooting	A – right Cerebellum (CB2) C – left dIPFC	2	0.057	20	Shooting score on 10 m shooting range	a-tDCS improved shooting score compared to sham
Kamali, Saadi et al., 2019		12 bodybuilders (all M)	3 training sessions/week	A1 – M1 (Cz, C1, C2) A2 – left TC (T3) C1 – right shoulder C2 – left shoulder	2	0.057 0.125	13	Short-term endurance index (SEI): knee extension AMRAP with 30% 1RM	a-tDCS improved SEI compared to sham
Mesquita et al., 2019		19 taekwondo black belts (7 F, 12 M)	7 taekwondo-specific training sessions, national & international competition	A1 – right M1 (C3) A2 – left M1 (C4) C1 – right shoulder C2 – left shoulder	1.5	0.057	15	Frequency speed of kick test (FSKT)	No significant difference in total number of kicks between a-tDCS and sham
Valenzuela et al., 2019	Crossover	8 triathletes (all M)	26–27 h/week, International competition	A – left M1 (C3) C – right supraorbital area (Fp2)	2	0.08	20	800 m freestyle swimming TT	No significant difference between a-tDCS and sham
Mesquita et al., 2020		12 taekwondo black belts (4 F, 8 M)	8.6 years, International & national competition		1.5	0.057	15	Progressive specific taekwondo test (PSTT)	No significant difference for peak kicking frequency between a-tDCS and sham
Pollastri et al., 2020	Crossover	8 cyclists (all M)	$Mean VO_2max = 72.2 mL\bullet min^{-1} \bullet kg^{-1}$		1.5	n.a.	20	15 km TT on cycle ergometer	a-HD-tDCS improved TT compared to sham
Chen et al., 2021		13 basketball players (all M)	Regular training	A – M1 (Cz) C – M1 (C5, C6) Halo-Sport	2	0.083	20	Power test (counter movement jump)	a-tDCS improved counter movement jump height compared to sham
da Silva Machado et al., 2021		12 endurance athletes (all M, 7 cyclists, 5 rowers)	Mean experience 6.9 years, 4.9 h/week	A - M1 (Cz) C - inion	2	0.056	20	Time to exhaustion (TTE) test with 80% PPO on cycle ergometer	No significant difference in TTE between a-tDCS and sham
2021		athletes (all M)	3-10 years, 3-5 sessions/week	A – M1 (Cz) C – right shoulder	2	0.08	20	Total number of parallel back squat repetitions with 15 RM over 10 sets	a-tDCS improved total back squat volume compared to sham
Grosprêtre et al., 2021		18 parkour athletes (all M)	Mean training volume: 4343 h	A – left M1 (FC2) C – left shoulder A – left dlPFC (F3) C – right supraorbital area	2	0.08	20	Compound jumping performance (standing long jump, squat jump, counter movement jump)	M1-tDCS improved jumping performance compared to sham No significant difference in performance between dlPFC-tDCS and sham
Kamali et al., 2021	Crossover	14 olympic boxers (all M)	2 years, 6 h/week	A1 – right M1 (C3) A2 – left M1 (C4) C1/2 – bilaterally adjacent to spinal processes C5-T1	2	0.125	13	Boxing specific reaction time task for both hands	a-tDCS improved reaction time of right and left hand compared to sham
Penna et al., 2021	Crossover	10 swimmers (all M)	7 h/week, competition at highest national level	A – left TC (T3) C – ipsilateral shoulder	2	0.057	30	800 m swimming TT	No significant difference in the 800 m swimming trial between a- tDCS and sham (continued on next page

Table 1 (continued)	( pənu								
Study	Design	Participants (F – female, M – male)	Training experience	Anode (A) Cathode (C)	Current intensity (mA)	Current Current Stimulati intensity density duration (mA) (mA/ (min) cm <sup>2</sup> )	Stimulation duration (min)	Current Stimulation Sport-specific motor performance density duration (mA/ (min) cm <sup>2</sup> )	Outcome
Fortes et al., 2022	Crossover	· 19 swimmers (all F)	Fortes et al., Crossover 19 swimmers (all F) 5 years, competition at regional level A – left oPFC (Fp1) 2022 C – right oPFC (Fp2	A – left oPFC (Fp1) C – right oPFC (Fp2)	2	0.08	30	3 min all-out tethered swimming	a-tDCS improved force minimum of tethered swimming compared to sham
Gallo et al., 2022	Crossover	Gallo et al., Crossover 11 cyclists (all M) 2022	Mean VO <sub>2</sub> max = 71.8 mL•min <sup>-1</sup> •kg <sup>-1</sup> A1 - left dlPFC (F3) 1.5 A2 - right dlPFC (F4) C1 - Fp1/F7/C3 C2 - Fp2/F8/C4 (HD-tDCS) C2 - Fp2/F8/C4 (HD-tDCS)	A1 – left dIPFC (F3) A2 – right dIPFC (F4) C1 – Fp1/F7/C3 C2 – Fp2/F8/C4 (HD- tDCS)	1.5	n.a.	20	2 km TT on cycle ergometer	a-tDCS tended to improve 5 km TT compared to sham
Liang et al., 2022	Crossover	Liang et al., Crossover 8 rowers (all F) 2022	Competitive performance ranking in top 8 in the national regatta, regular daily training	A – M1 (Cz) C – M1 (C5, C6) Halo-Sport	2.2	0.083	20	5 km TT on rowing ergometer	No significant difference in 5 km rowing time between a-tDCS and sham
Nikooharf Salehi et al., 2022	Crossover	· 15 swimmers (all M)	ational & national	A – left dlPFC (F3) C – right supraorbital area (Fp2)	2	0.057	20	50 m freestyle swimming trial in mentally fatigued state	a-tDCS improved freestyle swimming performance compared to sham
Park et al, 2022	Crossover	· 13 volleyball players (all F)	Crossover 13 volleyball players Professional V-League in Korea (all F)	A - M1 (Cz) C - M1 (C5, C6) Halo-Sport	7	0.083	20	Spiking consistency test (SD of spike ball a-tDCS improved spiking speed from 5 trials) consistency compared to	I a-tDCS improved spiking consistency compared to sham
Note: A/C – Ar	ode/Cathor	de; AMRAP – As Many I	Reps As Possible; a-tDCS – Anodal Trans	scranial Direct Current S	timulation	; dIPFC – I	Jorsolateral F	Note: A/C – Anode/Cathode; AMRAP – As Many Reps As Possible; a-tDCS – Anodal Transcranial Direct Current Stimulation; dIPFC – Dorsolateral Prefrontal Cortex; F/M – Female/Male; FSKT – Frequency Speed of Kick Test; HD-	KT – Frequency Speed of Kick Test; HD-

**Note:** A/C – Anode/Cathode; AMRAP – As Many Reps As Possible; a-tDCS – Anodal Transcranial Direct Current Stimulation; dIPFC – Dorsolateral Prefrontal Cortex; *FVM* – reutare/wate; 1911 – 1114 – 11

device in 3 studies (16%) and HD-tDCS in 2 studies (11%). One study compared conventional tDCS with HD-tDCS [51]. Because there were no differences between conventional tDCS and HD-tDCS in this study, the focus of the current review was on conventional tDCS. Additionally, a single study combined conventional tDCS with transcutaneous spinal current stimulation [44]. All studies applied tDCS prior to sport-specific performance. Cortical target areas of tDCS were clustered in 4 groups: M1 [3.24.40-42.44.48.50-52.54]. TC [39,41,53], PFC [3,23,45-47,49] and CB [43]. Current intensity was set at 2-2.2 mA in most studies (79%) or 1.5 mA (21%). Current density was set to 0.056–0.057 mA/cm<sup>2</sup> (42%), 0.08–0.083 mA/cm<sup>2</sup> (42%) or 0.125 mA/cm<sup>2</sup> (11%). Current was applied for a duration of either 20 min (68%), 12–15 min (21%), or 30 min (11%). Regarding sham procedures, the following protocols were used: sham protocols with different stimulation times between 5s (5%) [50], 15s (5%) [40], and 30s (79%) [3,23,24,39,41-46,48,49,52-54] that followed ramp-on and preceded ramp-off periods of 30s or less, an active sham protocol during HD-tDCS in which current was applied for the same duration as in the active condition although with different current intensities for the individual HD electrodes (5%) [51], and a sham protocol in which current was applied only during the first and last 30s of the stimulation period (5%) [47].

### 3.4. Quantitative analysis

#### 3.4.1. Overall effect

Across all included studies, a significant moderate standardized mean difference favoring anodal tDCS over sham for sport-specific motor performance changes could be observed (n = 19 studies, SMD = 0.31, 95%CI [0.14, 0.49], p < 0.001, see Fig. 3). Studies showed low heterogeneity (Chi<sup>2</sup> = 17.29, p = 0.50; l<sup>2</sup> = 0%). In addition, the funnel plot (Fig. 4) showed symmetrically scattered effect sizes, all but one within the funnel.

#### 3.4.2. Cortical target area subgroup analysis

Subgroup analysis depending on cortical target areas of tDCS (Fig. 3) indicated a significant moderate standardized mean difference in favor of anodal tDCS compared to sham for M1 (n = 11 studies, SMD = 0.33, 95%CI [0.07, 0.58], p = 0.01, Chi<sup>2</sup> = 11.32, p = 0.33; l<sup>2</sup> = 12%). Other target areas showed non-significant moderate to high SMD favoring anodal tDCS over sham: TC (n = 3 studies, SMD = 0.40, 95%CI [-0.10, 0.89], p = 0.12, Chi<sup>2</sup> = 0.70, p = 0.70; l<sup>2</sup> = 0%), PFC (n = 6 studies, SMD = 0.23, 95% CI [-0.04, 0.50], p = 0.09, Chi<sup>2</sup> = 4.47, p = 0.48; l<sup>2</sup> = 0%) and CB (n = 1 study, SMD = 0.89, 95%CI [-0.15, 1.94], p = 0.09, n.a.). No between subgroup differences were observed (Chi<sup>2</sup> = 1.65, df = 3, p = 0.65).

#### 3.4.3. Performance domain subgroup analysis

Performance domain subgroup analysis (Fig. 5) revealed a significant moderate standardized mean difference favoring anodal tDCS compared to sham for sport-specific performance changes in the visuomotor skill domain (n = 7 studies, SMD = 0.45, 95%CI [0.06, 0.85], p = 0.02, Chi<sup>2</sup> = 10.76, p = 0.10; l<sup>2</sup> = 44%). Non-significant moderate SMD were found for the other performance domains: endurance domain (n = 10 studies, SMD = 0.23, 95%CI [-0.01, 0.47], p = 0.06, Chi<sup>2</sup> = 5.13, p = 0.82; l<sup>2</sup> = 0%), strength domain (n = 2 studies, SMD = 0.44, 95%CI [-0.14, 1.01], p = 0.14, Chi<sup>2</sup> = 0.31, p = 0.58; l<sup>2</sup> = 0%). Also, no between subgroup differences were observed (Chi<sup>2</sup> = 1.16, df = 2, p = 0.56).

# 4. Discussion

We investigated the effects of tDCS on sport-specific performance changes in athletes. The idea of this study relates to the




Fig. 2. Risk of bias assessment according to Cochrane guidelines. The checklist consists of 7 items, with the following answers choices: "low risk of bias" ("+"), "high risk of bias" ("-"), or "unclear risk of bias" ("?").

fundamental debate regarding the scope of applicability of tDCS, in other words, the ecological validity of tDCS. Concerning motor performance, tDCS is predominantly employed in patients or healthy participants with proven ability to enhance motor performance [12–15]. However, the question remains whether performance-enhancing effects are also detectable in trained athletes, particularly in sport-specific motor tasks. Due to so-called "ceiling effects", it is assumed that performance enhancement becomes increasingly difficult to achieve as the level of performance increases [51]. A total of 19 studies were included in this meta-analysis. Overall, our results show a moderate effect of anodal tDCS on sport-specific performance changes in athletes compared to sham. To provide a better classification of tDCS effects, two additional subgroup analyses were performed, one on cortical target areas and one concerning the performance domain. These subgroup analyses revealed moderate effects for M1 stimulation

1.2.1 M1       Valenzuela et al. 2019       596       39       8       599       38       8       2.9%       -0.07 [-1.05, 0.91]       2019         Mesquita et al. 2019       3.204       961       12       2.662       763       12       4.1%       0.60 [-0.22, 1.42]       2019         Mesquita et al. 2019       93.1       5.2       19       94.6       6.5       19       6.8%       -0.25 [-0.89, 0.39]       2019         Mesquita et al. 2021       88.7       7       12       46.8       8.1       24.3%       0.28 [-0.53, 1.08]       2021         Grosperte et al. 2021       11.133       12       18       16.4%       0.30 [-0.36, 0.92]       2021         da Silva Machado et al. 2021       0.483       0.042       13       0.463       0.047       13       4.5%       0.38 [-0.34, 1.21]       20.21       2022         Liag et al. 2022      228.65       34.31       8       -1.237       33.03       8       2.8%       0.23 [-0.75, 1.22]       2022         Liag et al. 2015       313.2       29.9       10       301       19.8       10       3.5%       0.46 [-0.43, 1.35]       2015         Subtoal (95% C1)       12       2.662       763		tD	ocs		9	Sham		9	itd. Mean Difference		Std. Mean Difference	Risk of Bias
Valenzuela et al. 2019 596 39 8 599 38 8 29% -0.07, 1-05, 0.31 2019 Mesquita et al. 2019 93.1 5-2 19 94.6 6.5 19 6.8% -0.25 [-0.88, 0.39] 2019 Mesquita et al. 2021 93.1 5-2 19 94.6 6.5 19 6.8% -0.25 [-0.88, 0.39] 2019 forest et al. 2021 18.7 7 12 46.8 8.1 12 4.3% 0.38 0.66 2021 da Silva Machado et al. 2021 11.33 12 18 10.78 3 12 4.3% 0.38 0.06 [-0.22, 1.04] 2021 da Silva Machado et al. 2021 0.468 0.042 13 0.463 0.047 13 4.5% 0.39 [-0.36, 0.02] 2021 da Silva Machado et al. 2021 0.468 0.042 13 0.463 0.047 13 4.5% 0.48 [-0.34, 1.21] 2021 da Silva Machado et al. 2021 0.468 0.042 13 0.463 0.047 13 4.5% 0.48 [-0.34, 1.21] 2021 da Silva Machado et al. 2021 0.468 0.042 13 0.463 0.047 13 4.5% 0.48 [-0.34, 1.21] 2021 Ling et al. 2022 -2.42 1.221 13 -4.43 1 4.1 13 3.7% 0.43 [-0.34, 1.21] 2021 Ling et al. 2022 -2.42 1.221 10 ( $\theta = 0.33$ ); $l^{\pm} 1.2\%$ teterogenetity: Tau <sup>2</sup> = 0.02; Ch <sup>2</sup> = 10 ( $\theta = 0.33$ ); $l^{\pm} 1.2\%$ teterogenetity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.70; $l^{\pm} 0.05$ L22.67 C Notari effect: Z = 2.53 ( $\theta = 0.01$ ) L2.7 C Namal: scale 201 695. 43.5 10 689 42 12 30 46 [-0.43, 1.35] 2015 Meanget effect: Z = 0.00; Ch <sup>2</sup> = 0.70; $l^{\pm} 0.0\%$ A 46 [-0.43, 0.36] 2021 L2.8% 0.28 [-0.71, L27] 2022 Subtoal (95% CI) -1.21 25 28 -1.228 56 8 2.28% 0.28 [-0.71, L27] 2022 Subtoal (95% CI) -1.33, 7.3 13 12 5.741 1.73 15 -4.8% 0.34 [0.13] -0.57, 0.22 12 L2.47 C Neckmark 1, Xani et al. 2019 2.24 35.5 36 2.24 41.4 36 12.9% 0.00 [-0.46, 0.46] 2019 Conserve et al. 3021 6.93.5 43.5 10 689 42 13 0.76 0.88] 2021 L2.4 CE Kamali, Kami et al. 2019 2.24 35.5 36 2.34 41.4 36 12.9% 0.39 [-0.70, 120 202 Subtoal (95% CI) -1.33, 7.3 12 19.57, 7.4 12.73 120 2.28 Subtoal (95% CI) -1.43, 7.73 11 1.74, 8.6 2.28 Subtoal (95% CI) -1.43, 7.73 11 1.74, 8.6 2.28 Subtoal (95% CI) -1.43, 7.73 11 1.74, 8.6 2.28 Subtoal (95% CI) -1.43, 7.73 15 -3.74 1.77 12 -3.75 4.8% 0.34 [-0.70, 120 2022 Subtoal (95% CI) -1.43, 7.74 1.77 15 -6.8% Subtoal (95% CI) -1.43, 7.74 1.77 15 -6.8% Subtoal (95% CI) -2.88 2.5.8 2.5.8 0.89 [-0.15, 1.94	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI	ABCDEFG
Kamali, Saadi et al. 2019 3, 204 961 12 2,662 763 12 4.1% 0.06 $[-0.25, 1.42]$ 2019 Mesquita et al. 2020 47.9 7.9 12 46.8 6.1 12 4.3% 0.13 $[-0.67, 0.39]$ 2019 Mesquita et al. 2021 88.7 7.12 86.7 7 12 4.3% 0.13 $[-0.67, 0.39]$ 2010 Grosprete et al. 2021 111.33 12 18 10.763 12 18 6.4% 0.30 $[-0.35, 1.06]$ 2021 Grosprete et al. 2021 $-4.50$ 40 14 $-48.11$ 43.5 14 4.7% 0.72 $[-0.05, 1.49]$ 2021 Large et al. 2021 $-4.50$ 40 14 $-48.11$ 43.5 14 4.7% 0.72 $[-0.05, 1.49]$ 2021 Large et al. 2022 $-1.228.65$ 34.31 $3$ $-1.237$ 33.03 $18$ 2.8% 0.31 $[-0.56, 0.592]$ 2021 Large et al. 2022 $-1.228.65$ 34.31 $3$ $-1.237$ 33.03 $12$ 2.86 $-0.25 [-0.68]$ 2.22 $[-0.33]$ ( $b-2.22$ $[-0.33]$ ( $b-2.22$ $[-0.33]$ ( $b-2.22$ $[-0.33]$ $[-0.75, 1.22]$ 2022 Large et al. 2022 $-1.228.65$ 34.31 $3$ $-1.237$ 33.03 $13$ 2.8% 0.231 $[-0.75, 1.22]$ 2022 Large et al. 2022 $-1.228.65$ 34.31 $3$ $-1.237$ 33.03 $12$ 8.00 $[-0.43, 1.35]$ 2015 Kamali, Saadi et al. 2019 3.024 961 12 2,662 7763 12 4.1% 0.60 $[-0.23, 1.35]$ 2015 Weterogenetity. Tau <sup>2</sup> $= 0.02$ , Ch <sup>2</sup> $= 0.70$ , l <sup>2</sup> $= 0.68$ Test for overall effect: $Z = 1.56$ ( $\theta = 0.10$ ) L2.2 TC Okano et al. 2019 $-2.34$ 35.5 $36$ $-2.34$ 4.1.4 $36$ 12.9% $0.00 [-0.46, 0.46]$ 2019 Define et al. 2021 $-0.70$ , l <sup>2</sup> $= 20$ $-0.70$ , l <sup>2</sup> $= 0.5$ Test for overall effect: $Z = 1.56$ ( $\theta = 0.02$ ) L2.2 TC Okano et al. 2021 $-2.52$ $38$ $-1.228$ $55$ $8$ $2.8%$ $0.28 [-0.71, 1.27]$ 2020 Large et al. 2021 $-2.52$ $38$ $-2.28$ $13$ $38$ $-2.5\%$ $0.39 [-0.15, 1.54]$ Define et al. 2021 $-0.25$ $-2.58$ $-3.28$ $-3.38$ $-9.4(1.6, 1.50, 76]$ 2021 L2.2 TC Torts et al. 2021 $-2.52$ $-7$ $-8$ $8.8.25$ $1.3$ $-8$ $-2.5\%$ $0.39 [-0.15, 1.54]$ Define et al. 2022 $-1.43.3$ $7.3$ $11$ $-1.44.8$ $8.2$ $11$ $3.9\%$ $0.39 [-0.15, 1.54]$ Define et al. 2020 $-1.212$ $-2.58$ $-7.8$ $8.8.25$ $1.3$ $-2.5\%$ $0.39 [-0.15, 1.54]$ Define et al. 2020 $-1.22$ $-1.68$ ( $\theta = 0.09$ ) Tatal Gys Ch) $-2.28$ $-2.58$ $-2.88$ $100.0\%$ $0.31 [0.15, 0.48]$ Define et al. 2019 $-0.53$ $-7.78$ $-9.09$ Tas for overall effe	1.2.1 M1											
Kamali, Saadi et al. 2019 3, 204 961 12 2,662 763 12 4.1% 0.60 [ $-0.22$ , 1.42 2019 Mesquita et al. 2019 47.9 7.9 12 46.8 6.1 12 4.3% 0.319 c.0.39 2019 Mesquita et al. 2021 47.9 7.9 12 46.8 6.1 12 4.3% 0.319 c.0.50, 0.39 2019 fortes et al. 2021 11.1.3 12 18 10.763 12 18 6.4% 0.30 [ $-0.35$ , 0.69 [ $2.021$ ] Conserve et al. 2021 2.2% 27.8 27.8 12 7.943 27.1 21 24 4.3% 0.12 [ $-0.66$ , 0.92 [ $2.021$ ] Kamali et al. 2021 $-4.50$ 40 14 4.41.1 43.5 14 4.7% 0.72 [ $-0.05$ , 1.49 [ $2.021$ ] Lang et al. 2021 $-4.50$ 40 14 4.41.1 43.5 14 4.7% 0.72 [ $-0.05$ , 1.49 [ $2.021$ ] Lang et al. 2022 $-1.228.65$ 34.31 8 $-1.227$ 33.03 8 2.2% 0.231 [ $-0.75$ , 1.22 [ $2.023$ Subtotal (95% Ct) L2.2 TC Okano et al. 2011 $3.2$ 29.9 10 301 19.8 10 3.5% 0.46 [ $-0.32$ , 1.43 [ $2.012$ ] Lang et al. 2012 $-1.228.65$ 34.31 8 $-1.227$ 73.03 8 2.2% 0.231 [ $-0.75$ , 1.22 [ $2.022$ Jung et al. 2022 $-1.228.65$ 34.5 10 6.69 4.2 10 3.6% 0.10 [ $-0.27$ , 0.39 [ $2.01$ ] Heterogeneity. Tau <sup>2</sup> $= 0.02$ ; Ch <sup>2</sup> $= 1.132$ , df $= 10$ ( $P = 0.33$ ); t <sup>2</sup> $= 128$ test for overall effect: $Z = 1.56$ ( $P = 0.10$ ) L2.2 TC Okano et al. 2015 313.2 29.9 10 301 19.8 10 3.5% 0.46 [ $-0.23$ , 1.43 [ $2.015$ ] Meterogeneity. Tau <sup>2</sup> $= 0.02$ ; Ch <sup>2</sup> $= 1.132$ , df $= 10$ ( $P = 0.70$ ); t <sup>2</sup> $= 08$ Test for overall effect: $Z = 1.56$ ( $P = 0.10$ ) L2.2 TC Okano et al. 2015 313.2 2.9.9 10 301 19.8 10 3.5% 0.46 [ $-0.23$ , 1.42 [ $2.019$ ] Definite et al. 2020 $-1.212$ 52 8 $-1.228$ 55 8 2.8% 0.28 [ $-0.71$ , 1.27 [ $2.02$ ] L3.2 FPC Holgado et al. 2019 2.24 5.5 36 2.34 41.4 36 12.9% 0.00 [ $-0.46$ , 0.46] 2019 Distotal (95% Ct) $-1.212$ 52 8 $-1.3$ 8 2.5% 0.39 [ $-0.15$ , 1.54] L2.4 CB Kamali, Nami et al. 2021 $-2.52$ 7 8 8.8.25 1.3 8 2.5% 0.39 [ $-0.15$ , 1.54] Heterogeneity. Tau <sup>2</sup> $= 0.00$ ; Ch <sup>2</sup> $= 1.8.14$ , df $= 20$ ( $P = 0.58$ ); t <sup>2</sup> $= 0.56$ Test for overall effect: $Z = 1.56$ ( $P = 0.05$ ); t <sup>2</sup> $= 0.56$ Test for overall effect: $Z = 1.56$ ( $P = 0.05$ ); t <sup>2</sup> $= 0.56$ Test for overall effect: $Z = 1.56$ ( $P = 0.05$ ); t <sup>2</sup> $= 0.56$ Test for overall effect: $Z = 1.56$ ( $P = 0.$	Valenzuela et al. 2019	596	39	8	599	38	8	2.9%	-0.07 [-1.05, 0.91]	2019		9999999
Mesquita et al. 2019 93.1 5.2 19 94.6 6.5 19 6.8% -0.25 [-0.89, 0.39] 2019 fortes et al. 2021 88.7 7 12 86.6 7 7 12 4.3% 0.13 [-0.67, 0.93] 2020 fortes et al. 2021 88.7 7 12 86.6 7 7 12 4.3% 0.28 [-0.53, 1.08] 2021 da Silva Machado et al. 2021 827.8 72.7 12 79.4 27.1 2 14 4.3% 0.21 [-0.66, 0.96] 2021 da Silva Machado et al. 2021 827.8 72.7 11 2 79.4 27.1 2 12 4.3% 0.12 [-0.68, 0.96] 2021 da Silva Machado et al. 2021 827.8 72.7 11 2 79.4 27.1 2 12 4.3% 0.21 [-0.68, 0.96] 2021 da Silva Machado et al. 2021 - 0.48 0.042 13 0.463 0.047 13 4.5% 0.47 (-10.5, 149 2021 -1.22.46 5.3 4.1 12 4.33 1.1 3 3.7% 1.3 (16, 50.49) 2021 Heterogenety: Tau" = 0.00; Ch <sup>2</sup> = 0.70; l <sup>2</sup> = 0.7 Heterogenety: Tau" = 0.00; Ch <sup>2</sup> = 0.70; l <sup>2</sup> = 0.7 Test for overall effect: 2 - 2.53 (P = 0.01) L2.2 TC Notance et al. 2021 - 0.7, of $d = 2 (P = 0.70); l2 = 0.%$ Test for overall effect: 2 - 2.53 (P = 0.01) L2.3 PPC Test for overall effect: 2 - 2.53 (P = 0.01) L2.3 PPC Notogado et al. 2019 3.204 961 112 2.662 763 12 4.1% 0.610 [-0.76, 0.89] 2021 Subtoal (95% Cf) - 0.70; d <sup>2</sup> = 0.70; l <sup>2</sup> = 0.% Test for overall effect: 2 - 3.56 (P = 0.12) L2.3 PPC Nicobard Saleh et al. 2019 0.24 3.55 36 2.24 41.4 36 12.9% 0.00 [-0.46, 0.46] 2019 Olagano et al. 2021 693.5 4.35 10 6.59 4.21 13 6.55 0.10 [-0.70, 29 202] Nicobard Saleh et al. 2020 - 1.212 52 8 - 1.22 8 156 8 2.8% 0.38 [-0.71, 1.27] 2020 Dilation of 0.020; Ch <sup>2</sup> = 0.70; l <sup>2</sup> = 0.% Test for overall effect: 2 = 1.56 (P = 0.12) L2.4 CB Kamall, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.54] 2019 Subtoal (95% Cf) 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.54] 2019 Diag (-0.46, 0.50] Test for overall effect: 2 = 1.68 (P = 0.09) Test for overall effect: 2 = 1.68 (P = 0.09) Test for overall effect: 2 = 1.68 (P = 0.09) Test for overall effect: 2 = 1.68 (P = 0.09) Test for overall effect: 2 = 1.68 (P = 0.09) Test for overall effect: 2 = 1.68 (P = 0.002) Test for overall effect: 2 = 1.68 (P = 0.002) Test for overall effect: 2 = 1.68 (P = 0.002) Test for		3,204		12	2,662	763	12					
Mesquitz et al. 2020 Fortes et al. 2021 Grosperter et al. 2021 Grosperter et al. 2021 Grosperter et al. 2021 Handli Silva Machado et al. 2021 Asmall et al. 2021 Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.32; df = 10 ( $P$ = 0.33); l <sup>2</sup> = 1.38 Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 2.9 = 0.70; l <sup>2</sup> = 0.0K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 2.9 = 0.70; l <sup>2</sup> = 0.0K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 2.9 = 0.70; l <sup>2</sup> = 0.0K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 2.7 & 8 Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 2.9 = 0.70; l <sup>2</sup> = 0.0K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 2.9 = 0.70; l <sup>2</sup> = 0.0K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 2.9 = 0.70; l <sup>2</sup> = 0.0K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 2.7 & 8 Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 2.7 & 8 Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.55, df = 0 (P = 0.58); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.55, df = 0 (P = 0.58); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.55, df = 0 (P = 0.58); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.55, df = 0 (P = 0.58); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.55, df = 0 (P = 0.58); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.55, df = 0 (P = 0.58); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.55, df = 0 (P = 0.58); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.55, df = 0 (P = 0.58); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.55, df = 0 (P = 0.56); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 1.55, df = 0 (P = 0.56); l <sup>2</sup> = 0.6K Heterogenetry: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup>	Mesquita et al. 2019	93.1	5.2	19	94.6	6.5	19	6.8%				
Fortes et al. 2021 88.7 7 12 86.7 7 12 4.3% 0.28 [-0.53, 1.08] 2021 (consperse tal. 2021 11.33 12 18 6.74 1.4 1.5 14 4.75 4.0 4.75 0.63 6, 0.95 2021 da Silva Machado et al. 2021 827.8 27.8 7 12 79.4 27.12 12 4.3% 0.12 [-0.68, 0.92] 2021 (consperse tal. 2021 0.483 0.44 2 13 0.463 0.47 13 4.5 14 4.75 0.77 0.72 [-0.05, 1.49] 2021 (consperse tal. 2022 - 2.48 1.21 13 - 4.33 1.4 1 13 3.75 1.4 (consperse tal. 2022 - 2.28.65 3.4.31 8 - 1.237 3.30.3 8 2.8% 0.23 [-0.75, 1.22] 2022 (consperse tal. 2022 - 2.28.65 3.4.31 8 - 1.237 3.30.3 8 2.8% 0.23 [-0.75, 1.22] 2022 (consperse tal. 2022 - 2.28.65 3.4.31 1 2 2.662 763 12 4.1% 0.33 [0.07, 0.58] 2021 Heterogeneity. Tau <sup>2</sup> = 0.0.21 12 2.662 763 12 4.1% 0.66 [-0.43, 1.35] 2015 Marmali, Saad et al. 2019 3.24 95 1 2 2.662 763 12 4.1% 0.66 [-0.22, 1.42] 2019 Penna et al. 2021 6.9.25 4.3.5 10 6.89 42 10 3.6% 0.46 [-0.74, 0.98] 2021 Meterogeneity. Tau <sup>2</sup> = 0.00, Ch <sup>2</sup> = 0.70, df = 2 ( $P = 0.70$ ); $l^2 = 0.8$ 22 11.1% 0.40 [-0.16, 0.46] 2019 Penna et al. 2012 1.63 2.5 36 2.34 41.4 36 12.9% 0.00 [-0.46, 0.46] 2019 Penna et al. 2020 - 1.212 52 8 -1.228 56 8 2.8% 0.28 [-0.74, 1.27] 2020 Crasperter et al. 2021 1.08.33 11 18 10.763 12 118 6.5% 0.11 [-0.54, 0.76] 2021 Penna et al. 2022 - 2.53 1 1.3 1.2 1.2.74 1.73 13 6.5% 0.11 [-0.54, 0.76] 2022 Crasperter et al. 2021 1.33 7.3 11 - 14.48 8 2.5% 0.89 [-0.15, 1.94] 2019 Penna et al. 2022 - 2.53 1 1.3 2 1.2.74 1.73 11 3.9% 0.19 [-0.54, 0.76] 2022 Crasperter et al. 2021 1.33 7.3 11 - 14.4 8 2.79 (consperter et al. 2021 1.2.66 (P = 0.09) Total 95% CO) 1.2.2 1.2.3 7.7% 0.23 [-0.04, 0.50] Penna et al. 2019 Penna et al. 2020 Penna Pe	Mesquita et al. 2020	47.9	7.9	12	46.8	8.1	12	4.3%				
Groeperter et al. 2021 111.33 12 18 107.63 12 18 6.4% 0.30 [-0.36, 0.96] 2021 da Silva Machado et al. 2021 450 40 14 461.1 43.5 14 4.7% 0.72 [-0.65, 0.92] 2021 Acanali et al. 2022 -4.84 1.21 13 -4.63 0.47 13 4.5% 0.43 [-0.54, 0.21] 2021 Dark et al. 2022 -2.84 1.21 13 -4.33 1.41 13 3.7% 1.36 [0.50, 2.23] 2022 Subtoal (95% C) -1.22.865 3.4.3 14 4 .33 3. 86 2.3% 0.23 [-0.75, 1.22] 2022 Subtoal (95% C) -0.12 2.26 (-0.12) -1.2 2.66 -2.3 3.1 12 2.66 -2.7 12 4.1% 0.51 (-0.45, 1.35) 2015 Subtoal (95% C) -0.00; Ch <sup>2</sup> = 0.70, df = 2.( $P = 0.39$ ); $l^2 = 12\%$ Test for overall effect: $Z = 0.60$ , Ch <sup>2</sup> = 0.70, df = 2.( $P = 0.70$ ); $l^2 = 0\%$ Test for overall effect: $Z = 1.56 (P = 0.12)$ Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.70, df = 2.( $P = 0.70$ ); $l^2 = 0\%$ Test for overall effect: $Z = 1.56 (P = 0.12)$ Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.70, df = 2.( $P = 0.70$ ); $l^2 = 0\%$ Test for overall effect: $Z = 1.68 (P = 0.12)$ Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 4.47, df = 5 ( $P = 0.48$ ); $l^2 = 0\%$ Subtoal (95% C) -0.13 1.1 18 10.763 12 18 6.5% 0.41 (-0.45, 1.127) 2022 Groeperter et al. 2021 108.33 11 18 10.763 12 18 6.5% 0.41 (-0.46, 0.46] 2019 Nicohard Salehi et al. 2022 -25.58 1.3 132 15 -27.41 1.73 15 4.8% 0.94 (0.16, 1.70) 2022 Groeperter et al. 2021 108.33 11 14 18 10.763 12 18 6.5% 0.31 (-0.54, 0.76] 2021 Forter set al. 2022 108.53 13.2 15 -27.41 1.73 15 4.8% 0.94 (0.16, 1.70) 2022 Groeperter et al. 2021 108.93 11 14 18 10.763 12 18 6.5% 0.31 (-0.55, 1.02) 2022 Subtoal (95% C) -2.2.7 8 8 8.2.5 1.3 8 2.5% 0.89 (-0.15, 1.94) Subtoal (95% C) -2.2.7 8 8 8.2.5 1.3 8 2.5% 0.89 (-0.15, 1.94) Subtoal (95% C) -2.2.7 8 8 8.2.5 1.3 8 2.5% 0.39 (-0.15, 1.94) Subtoal (95% C) -2.2.7 8 8 8.2.5 1.3 8 2.5% 0.39 (-0.15, 1.94) Subtoal (95% C) -2.2.7 8 8 8.2.5 1.3 8 2.5% 0.39 (-0.15, 1.94) Subtoal (95% C) -2.2.7 8 8 8.2.5 1.3 8 2.5% 0.39 (-0.15, 1.94) Subtoal (95% C) -2.2.7 8 8 8.2.5 1.3 8 2.5% 0.39 (-0.15, 1.94) Subtoal (95% C) -2.2.7 8 8 8.2.5 1.3 8 2.5% 0.39 (-0.15, 1.94) Subtoal (95% C) -2.2.7 8 8		88.7		12	86.7	7	12					
da Silva Machado et al. 2021 $627.8$ 27.8, 7 12 79.4 3 27.1, 2 12 4.3% $0.12 (-0.66, 0.92)$ 2021 Chen et al. 2021 $0.438 0.042$ 13 $0.463 0.047$ 13 4.5 14 4.37, $0.72 (-0.05, 1.49)$ 2021 Chen et al. 2022 $-2.48$ 1.21 13 $-4.33$ 1.4 13 3.5 14 $4.5\%$ $0.43 (-0.34, 1.21)$ 2021 Liang et al. 2022 $-1.228.65 34.31$ 8 $-1.237 33.03$ 8 2.8% $0.231 (-0.75, 1.22)$ 2022 Liang et al. 2022 $-1.228.65 34.31$ 8 $-1.237 33.03$ 8 2.8% $0.231 (-0.75, 1.22)$ 2022 Distoited (95% Ct) $1.41$ 14 48.7% $0.33 (0.07, 0.58]$ Heterogeneity: Tau <sup>2</sup> = 0.02; Ch <sup>2</sup> = 1.32, df = 10 (P = 0.33); l <sup>2</sup> = 1.2% Test for overall effect: $2 - 2.53 (P = 0.04)$ L2.2 TC Okano et al. 2015 313.2 29.9 10 301 19.8 10 3.5% $0.46 (-0.43, 1.35]$ 2015 Mamali, Saadi et al. 2019 313.2 29.9 10 301 19.8 10 3.5% $0.40 (-0.22, 1.42)$ 2019 Penna et al. 2012 $-0.00;$ Ch <sup>2</sup> = 0.70; l <sup>2</sup> = 0% Test for overall effect: $2 - 1.56 (P = 0.12)$ L2.3 PFC Molgato et al. 2019 2.24 35.5 36 2.34 41.4 36 12.9% $0.00 (-0.46, 0.46)$ 2019 Mileobard 15 2010 $-1.212$ 52 8 $-1.228$ 56 8 2.28% $0.28 (-0.71, 1.27)$ 2020 Test for overall effect: $2 - 1.56 (P = 0.12)$ L3.3 PFC Molgato et al. 2012 $-2.53 $ 1.3 15 $-2.741$ 1.73 18 6.5% $0.11 (-0.54, 0.76)$ 2021 Torist et al. 2022 $-2.53$ 1.3 15 $-2.741$ 1.73 18 6.5% $0.28 (-0.74, 0.22)$ 2022 Mileobard 15% Ct) $-1.33$ 7.7 $10 - 74.48$ 8 2.10 $3.6\%$ $0.23 (-0.75, 1.29)$ 2022 Mileobard 15% Ct) $-1.33$ 7.7 $10 - 74.48$ 8 2.5% $0.89 (-0.15, 1.94)$ 2019 Mileobard 15% Ct) $-1.33$ 7.7 $10 - 74.48$ 8 2.5% $0.89 (-0.15, 1.94)$ 2019 Mileobard 15% Ct) $-1.68 (P = 0.09)$ Test for overall effect: $2 - 1.68 (P = 0.09)$ Test for overall effect: $2 - 1.68 (P = 0.09)$ Test for overall effect: $2 - 1.68 (P = 0.009)$ Test for overall effect: $2 - 1.68 (P = 0.009)$ Test for overall effect: $2 - 1.68 (P = 0.009)$ Test for overall effect: $2 - 1.68 (P = 0.009)$ Test for overall effect: $2 - 1.68 (P = 0.009)$ Test for overall effect: $2 - 1.68 (P = 0.009)$ Test for overall effect: $2 - 1.68 (P = 0.009)$ Test for overall effect: $2 - 1.$		111.33	12	18	107.63	12	18	6.4%			+	
Kamali tal. 2021 -450 40 14 -481.1 43.5 14 4.7% 0.72 [-0.51, 149] 2021 Chen et al. 2021 -4.83 0.047 13 0.463 0.047 13 0.463 0.047 13 0.450 0.47 1.21 2021 Park et al. 2022 -2.48 1.21 13 -4.33 1.41 13 3.7% 1.36 [0.50, 2.23 2022 Subtoal (95% CI) -1.12.26.65 34.31 8 -1.237 33.03 8 2.8% 0.23 [-0.75, 1.22] 2022 Subtoal (95% CI) -1.22.26.67 34.31 14 48.7% 0.33 [0.07, 0.58] DKano et al. 2015 31.32 29.9 10 301 19.8 10 3.5% 0.46 [-0.43, 1.35] 2015 Kamali, Sadi et al. 2019 3.204 961 12 2.662 763 12 4.1% 0.60 [-0.22, 1.42] 2019 Pana et al. 2021 693.5 43.5 10 669 21 10 3.6% 0.10 [-0.78, 0.88] 2021 Subtoal (95% CI) -1.21 52 8 -1.228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 Test for overall effect: Z = 1.56 ( $P = 0.70$ ; $P = 0.70$ ; $P = 0.8$ Test for overall effect: Z = 1.56 ( $P = 0.12$ ) <b>1.2. PTC</b> Holgado et al. 2019 2.24 35.5 36 234 41.4 36 12.9% 0.00 [-0.46, 0.46] 2019 Pollastri et al. 2020 -1.212 52 8 -1.228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 Grosperte et al. 2021 -2.593 1.32 15 -2.7.1 19 6.7% 0.30 [-0.34, 0.18] 1.702 2022 Grosperte et al. 2021 -2.593 1.32 15 -2.7.1 19 6.7% 0.30 [-0.46, 0.46] 2019 Pollastri et al. 2022 -2.593 1.32 15 -2.7.1 19 6.7% 0.30 [-0.46, 0.50] 2022 Galo et al. 2022 -1.43 7.3 11 -144.8 8.2 11 3.9% 0.19 [-0.55, 1.02] 2022 Galo et al. 2022 -1.43.3 7.3 11 -144.8 8.2 11 3.9% 0.19 [-0.55, 1.02] 2022 Galo et al. 2022 -1.43.3 7.3 11 -144.8 8.2 5.5% 0.89 [-0.15, 1.94] 2019 Heterogeneity: Tau" = 0.00; Chi <sup>2</sup> = 4.7, df = 5 ( $P = 0.45$ ); $P = 0.05$ Test for overall effect: Z = 1.68 ( $P = 0.05$ ); $P = 0.05$ Test for overall effect: Z = 1.68 ( $P = 0.05$ ); $P = 0.05$ Test for overall effect: Z = 1.68 ( $P = 0.05$ ); $P = 0.05$ Test for overall effect: Z = 1.68 ( $P = 0.05$ ); $P = 0.05$ Test for overall effect: Z = 1.68 ( $P = 0.05$ ); $P = 0.05$ Test for overall effect: Z = 1.68 ( $P = 0.05$ ); $P = 0.05$ Test for overall effect: Z = 1.68 ( $P = 0.05$ ); $P = 0.05$ Test for overall effect: Z = 1.68 ( $P = 0.05$ ); $P = 0.05$ Test for overall effect: Z = 1.68 ( $P = 0.05$ ); $P = 0.05$ Test for overall e		827.8	278.7	12	794.3	271.2	12	4.3%				
Chen et al. 2021 0.483 0.042 13 0.463 0.047 13 4.5% 0.43 $[-0.34, 1.21]$ 2021 Park et al. 2022 -2.48 1.21 13 -4.33 1.41 13 3.7% 1.36 $[0.50, 2.23]$ 2022 Liang et al. 2022 -1.228.65 34.31 8 -1.237 33.03 8 2.8% 0.23 $[-0.75, 1.22]$ 2022 Diang et al. 2022 -1.228.65 34.31 8 -1.237 33.03 8 2.8% 0.23 $[-0.75, 1.22]$ 2022 Test for overall effect: Z = 2.53 ( $P = 0.01$ ) Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 1.132, df = 10 ( $P = 0.33$ ); l <sup>2</sup> = 12% Test for overall effect: Z = 2.53 ( $P = 0.01$ ) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.70; l <sup>2</sup> = 0.76 76 312 4.14 36 0.46 $[-0.43, 1.35]$ 2015 Meterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.70; l <sup>2</sup> = 0.70; l <sup>2</sup> = 0.8 Test for overall effect: Z = 1.56 ( $P = 0.12$ ) L.23 PFC Holgsdo et al. 2019 234 35.5 36 234 41.4 36 12.9% 0.00 $[-0.46, 0.46]$ 2019 Ponlastri et al. 2020 -1.212 52 8 -1.228 56 8 2.28% 0.28 $[-0.71, 1.27]$ 2022 Test for overall effect: Z = 1.56 ( $P = 0.02$ ) L.23 PFC Holgsdo et al. 2020 -1.212 55 8.3 19 52.67 11 19 6.7% 0.30 $[-0.34, 0.46]$ 2022 Hotesogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 ( $P = 0.48$ ); l <sup>2</sup> = 0.8 Test for overall effect: Z = -1.68 ( $P = 0.09$ ) Lact CB Kamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 $[-0.15, 1.94]$ 2019 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.8.14, df = 20 ( $P = 0.58$ ); l <sup>2</sup> = 0.8 Test for overall effect: Z = -1.68 ( $P = 0.09$ ) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ); l <sup>2</sup> = 0.8 Test for overall effect: Z = 1.68 ( $P = 0.09$ ) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ); l <sup>2</sup> = 0.8 Test for overall effect: Z = 1.68 ( $P = 0.09$ ) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ); l <sup>2</sup> = 0.8 Kar dial.agend (A) Randon sequence generation (selection bias) (B) Binding of participants and personnel (beerformance bias) (C) Binding of participants a	Kamali et al. 2021	-450	40	14	-481.1	43.5	14	4.7%				9999999
Park et al. 2022 -2.48 1.21 13 -4.33 1.41 13 3.7% 1.36 [0.50, 2.23 2022 Jubic Jubic Jubi	Chen et al. 2021	0.483	0.042	13	0.463		13	4.5%				
Subtool (95% C) 141 112 1132 (11 48.7% 0.33 [0.07, 0.58] 141 48.7% 0.33 [0.07, 0.58] 141 48.7% 0.33 [0.07, 0.58] 142 7C 06ano et al. 2015 313.2 29.9 10 301 19.8 10 3.5% 0.46 [-0.43, 1.35] 2015 143 48.7% 0.46 [-0.43, 1.35] 2015 144 36 12.9% 0.46 [-0.43, 1.35] 2015 145 49.7% 0.46 [-0.43, 1.35] 2015 145 49.7% 0.46 [-0.40, 0.88] 2021 145 49.7% 0.46 [-0.40, 0.46] 2019 145 49.7% 0.46 [-0.40, 0.46] 2019 142 52 32 32 11.1% 0.40 [-0.10, 0.88] 145 49.7% 0.46 [-0.40, 0.46] 2019 142 52 8 -1.228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 142 52 8 -1.228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 155 48.8% 0.94 [0.18, 1.00] [-0.46, 0.46] 2019 142 52 52 8 -1.228 56 8 2.8% 0.38 [-0.21, 1.27] 2020 155 67 58 et al. 2022 -1.43.3 7.3 11 -144 8.2 11 3.9% 0.09 [-0.45, 1.02] 2022 167 97 41 1.73 15 4.8% 0.94 [0.18, 1.00] [-0.22, 1.02] 2022 167 97 41 1.73 15 4.8% 0.94 [0.18, 1.00] [-0.22, 1.02] 2022 167 97 41 1.73 15 4.8% 0.94 [0.18, 1.00] [-0.22, 1.02] 2022 167 97 37.7% 0.23 [-0.04, 0.50] [0.22 167 97 37.7% 0.23 [-0.04, 0.50] [0.27 167 98 20 20 (Ch <sup>2</sup> = 1.68 (P = 0.09) 174 98 2.5% 0.89 [-0.15, 1.94] [0.19 167 98 C1) 288 2.5% 0.89 [-0.15, 1.94] [0.19 167 98 C1) 288 2.5% 0.89 [-0.15, 1.94] [0.19 167 98 C1) 288 2.5% 0.89 [-0.15, 1.94] [0.19 169 160.90 0 (Ch <sup>2</sup> = 1.68, Ch <sup>2</sup> = 0.90, Ch <sup>2</sup> = 1.68 (P = 0.05); 1 <sup>2</sup> = 0% 154 for subgroup differences: Ch <sup>2</sup> = 1.68 (P = 0.05); 1 <sup>2</sup> = 0% 154 for subgroup differences: Ch <sup>2</sup> = 1.68 (P = 0.05); 1 <sup>2</sup> = 0% 154 for subgroup differences: Ch <sup>2</sup> = 1.68 (P = 0.05); 1 <sup>2</sup> = 0% 154 for subgroup differences: Ch <sup>2</sup> = 1.68 (P = 0.05); 1 <sup>2</sup> = 0% 154 for subgroup differences: Ch <sup>2</sup> = 1.68, d <sup>2</sup> = 0 (P = 0.56); 1 <sup>2</sup> = 0% 154 for subgroup differences: Ch <sup>2</sup> = 1.68 (P = 0.65); 1 <sup>2</sup> = 0% 154 for subgroup differences: Ch <sup>2</sup> = 1.68 (P = 0.65); 1 <sup>2</sup> = 0% 154 for subgroup d	Park et al. 2022	-2.48	1.21	13	-4.33	1.41	13	3.7%				
Subtotal (95% C) 141 141 48.7% 0.33 [0.07, 0.58] Heterogeneity: $Tau^2 = 0.02; Ch^2 = 1.132; df = 10 (P = 0.33); l^2 = 12%$ Test for overall effect: $Z = 2.53 (P = 0.01)$ 1.2.2 TC Okano et al. 2015 313.2 29.9 10 301 19.8 10 3.5% 0.46 [-0.43, 1.35] 2015 Kamali, Sadi et al. 2019 3.204 961 12 2,662 763 12 4.1% 0.60 [-0.21, 1.42] 2019 Penna et al. 2020 693.5 43.5 10 689 42 10 3.6% 0.10 [-0.76, 0.88] 2021 Subtoal (95% C) 232 32 11.1% 0.40 [-0.10, 0.89] Heterogeneity: $Tau^2 = 0.00; Ch^2 = 0.70; l^2 = 0.70; l^2 = 0.%$ Test for overall effect: $Z = 1.56 (P = 0.72)$ 1.2.3 PFC Holgado et al. 2021 10.8.39 11 18 107.63 12 18 6.5% 0.11 [-0.46, 0.46] 2019 Pollastri et al. 2022 125 8.3 19 52.6 7.1 19 6.7% 0.30 [-0.34, 0.54] 2022 Subtoal (95% C) -1.212 52 8 -1.228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 Grospretre et al. 2021 10.8.39 11 18 107.63 12 18 6.5% 0.11 [-0.46, 0.46] 2021 Forts et al. 2022 -1.43.3 7.3 11 -144.8 8.2 113 .9% 0.09 [-0.65, 1.02] 2022 Subtoal (95% C) -1.43.3 7.3 11 -144.8 .22 110 -3.7% 0.23 [-0.04, 0.50] 1.2.4 CB Kamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtoal (95% C) -28.6 (P = 0.09) 1.2.4 CB Kamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] Test for overall effect: $Z = 1.68 (P = 0.09)$ 1.2.4 CB Kamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] Test for overall effect: $Z = 1.68 (P = 0.09)$ Total (95% C) 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = -0.48); l <sup>2</sup> = 0% Kik of bais legand (A) Random sequence generation (selection bias) (B) Binding of participants and personnel (performance bias) (D) Binding of participants and personnel (performance bias) (C) Binding of p	Liang et al. 2022	-1,228.65	34.31	8	-1,237	33.03	8	2.8%	0.23 [-0.75, 1.22]	2022		6666666
Test for overall effect: $Z = 2.53 (P = 0.01)$ L2.2 TC Okano et al. 2015 313.2 29.9 10 301 19.8 10 3.5% 0.46 [-0.43, 1.35] 2015 Kamali, Sandi et al. 2019 3.204 961 12 2,662 763 12 4.1% 0.60 [-0.22, 1.42] 2019 Phena et al. 2021 693.5 43.5 10 669 42 10 3.6% 0.10 [-0.78, 0.98] 2021 Subtoal (95% C) 232 31.1% 0.40 [-0.10, 0.89] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.70, df = 2 (P = 0.70); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.68 (P = 0.42)$ Total (95% C) 288 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.68 (P = 0.09)$ L2.4 CB Kamali, Nami et al. 2019 9.0.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.68 (P = 0.09)$ L2.4 CB Kamali, Nami et al. 2019 9.0.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] Test for overall effect: $Z = 1.68 (P = 0.09)$ Total (95% C) 288 Test for overall effect: $Z = 1.68 (P = 0.09)$ Total (95% C) 288 Meterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 3 (P = 0.65); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.68 (P = 0.09)$ Total (95% C) 288 Meterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 3 (P = 0.65); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.68 (P = 0.09)$ Total (95% C) 288 Marcial Anom sequence generation (selection bias) (G) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (C) Blinding of participants and personnel (performance	Subtotal (95% CI)	•		141			141	48.7%			◆	
Okano et al. 2015 313.2 29.9 10 301 19.8 10 3.5% 0.46 [-0.43, 1.35] 2015 Kamali, Saadi et al. 2019 3.204 961 12 2.662 763 12 4.1% 0.60 [-0.22, 1.42] 2019 Prena et al. 2021 693.5 43.5 10 689 42 10 3.6% 0.010 [-0.78, 0.98] 2021 Subtoal (95% C) 4.2 ( $P = 0.70$ ); $I^2 = 0\%$ Test for overall effect: $Z = 1.56 (P = 0.12)$ 1.2.3 PFC Holgado et al. 2019 234 35.5 36 234 41.4 36 12.9% 0.00 [-0.46, 0.46] 2019 Pollastri et al. 2020 -1.212 52 8 -1.228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 Grospretre et al. 2021 108.93 11 18 107.63 12 18 6.5% 0.11 [-0.54, 0.76] 2021 Fortes et al. 2022 -25.93 1.32 15 -27.41 1.73 15 4.8% 0.94 [-0.43, 1.02] 2022 Subtoal (95% C) -14.3 7.3 11 -14.4 8.2 11 3.9% Callo et al. 2022 -25.93 1.32 15 -27.41 1.73 15 4.8% 0.94 [-0.48, 1.70] 2022 Subtoal (95% C) -107 37.7% 0.23 [-0.04, 0.50] 12.2 4C8 Kamali, Nami et al. 2019 9.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtoal (95% C) -8 8 2.5% 0.89 [-0.15, 1.94] 2019 12.4 CB Kamali, Nami et al. 2019 9.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Test for overall effect: $Z = 1.68 (P = 0.09)$ 12.4 CB Kamali, Nami et al. 2019 9.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Literogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.68 (P = 0.00)$ Total (95% C) 8 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: $Z = 3.68 (P = 0.002)$ Total (95% C) 288 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: $Z = 3.68 (P = 0.002)$ Total (95% C) 288 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.5, df = 3 (P = 0.65); l <sup>2</sup> = 0% Rik of bias leaded (A) Random seassment (detection bias) (C) Blinding of outcome assessment (detection bias) (C) Blinding of outcome assessment (detection bias) (C) Blinding of outcome data (attrition bias) (C) Blinding of outcome data (attrition bias) (C) Blinding of			df = 10	(P = 0.	33); I <sup>2</sup> =	12%						
Kanali, Sadi et al. 2019 3, 204 961 12 2,662 763 12 4,1% 0,60 ( $-0.22$ , 1,42 2019 Penna et al. 2021 693.5 43.5 10 689 42 10 3,6% 0,10 ( $-0.78$ , 0,98 2021 Subtotal (95% C) 69 - 0.70, df = 2 ( $P = 0.70$ ); l <sup>2</sup> = 0% Test for overall effect: 2 = 1.56 ( $P = 0.70$ ); l <sup>2</sup> = 0% Test for overall effect: 2 = 1.56 ( $P = 0.22$ ) 1.2.3 PFC Holgado et al. 2012 2, 52 8 - 1,228 56 8 2,28% 0,28 ( $-0.71$ , 1,27 2020 Grosperte et al. 2021 108,93 11 18 107,63 12 18 6,5% 0,11 ( $-0.54$ , 0,76 2021 Forts et al. 2022 55 8,3 19 5,26 7,1 19 6,7% 0,30 ( $-0.45$ , 0,46 2021 Nikooharf Salehi et al. 2022 - 25,93 1,32 15 -27,41 1,73 15 4,8% 0,94 ( $0.18$ , 1,70 2022 Callo et al. 2022 - 143.3 7,3 11 -144.8 8,2 11 3,9% 0,19 ( $-0.65$ , 1,02 2022 Subtotal (95% C) -143.3 7,3 11 -144.8 8,2 11 3,9% 0,19 ( $-0.65$ , 1,02 2022 Subtotal (95% C) -2,1 +47, df = 5 ( $P = 0.48$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 1.68 ( $P = 0.09$ ) 1.2.4 CB Kamali, Nami et al. 2019 90.25 2,7 8 88.25 1,3 8 2,5% 0,89 ( $-0.15$ , 1,94 2019 Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 18.14, df = 20 ( $P = 0.58$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 1.68 ( $P = 0.009$ ) 1.2.4 CB Kamali, Nami et al. 2019 90.25 2,7 8 88.25 1,3 8 2,5% 0,89 ( $-0.15$ , 1,94 2019 Meterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 18.14, df = 20 ( $P = 0.58$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 1.68 ( $P = 0.009$ ) Total (95% C) 288 288 100.0% 0,31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 18.14, df = 20 ( $P = 0.58$ ); l <sup>2</sup> = 0% Test for overall effect: Z = 1.68 ( $P = 0.002$ ) Total (95% C) 288 288 100.0% 0,31 [0.15, 0.48] (B) Allocation concealment (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (C) Blinding	1.2.2 TC											
Penna et al. 2021 693.5 43.5 10 689 42 10 3.6% 0.10 [-0.78, 0.98] 2021 Subtoral (95% CI) 32 32 11.1% 0.40 [-0.10, 0.89] 2021 Test for overall effect: $Z = 1.56 (P = 0.12)$ 1.2.3 PFC Holgado et al. 2019 234 35.5 36 234 41.4 36 12.9% 0.00 [-0.46, 0.46] 2019 Pollastri et al. 2020 -1.212 52 8 -1.228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 Grospretre et al. 2021 0.89.3 11 18 107.63 12 18 6.5% 0.11 [-0.54, 0.76] 2021 Fortes et al. 2022 55 8.3 19 52.6 7.1 19 6.7% 0.30 [-0.34, 0.94] 2022 Subtoral (95% CI) -1.44.8 8.2 11 3.9% 0.19 [-0.54, 0.76] 2021 Fortes et al. 2022 -24.33 7.3 11 -144.8 8.2 11 3.9% 0.19 [-0.54, 0.76] 2021 Subtoral (95% CI) -1.44.8 7.3 11 -144.8 8.2 11 3.9% 0.23 [-0.04, 0.50] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.68 (P = 0.09)$ 1.2.4 CB Kamail, Nami et al. 2019 9.025 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtoral (95% CI) -288 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.8.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.68 (P = 0.009)$ Test for overall effect: $Z = 1.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ Test for overall effect: $Z = 3.68 (P = 0.002)$ (B) Allocation concelement (selection bias) (B) Allocation concelement (selection bias) (C) Blinding of outcome assessment (detection bias) (C) Blinding of									0.46 [-0.43, 1.35]	2015	+	9999999
Subtotal (95% C1) 32 32 11.1% 0.40 [-0.10, 0.89] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.70, df = 2 ( $P = 0.70$ ); $I2 = 0\%$ Test for overall effect: Z = 1.56 ( $P = 0.20$ ) 1.2.3 PFC Holgado et al. 2019 234 35.5 36 234 41.4 36 12.9% 0.00 [-0.46, 0.46] 2019 Pollastri et al. 2020 -1,212 52 8 -1,228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 Grosperter et al. 2021 108.93 11 18 107.63 12 18 6.5% 0.11 [-0.54, 0.76] 2021 Fortes et al. 2022 .55 8.3 19 52.6 7.1 19 6.7% 0.30 [-0.34, 0.34] 2022 Kilkoohaf Saleh et al. 2022 .2.93 1.32 15 -27.41 1.73 15 4.4% 0.94 [0.18, 1.70] 2022 Gallo et al. 2022143.3 7.3 11 -144.8 8.2 11 3.9% 0.19 [-0.65, 1.02] 2022 Gallo et al. 2022143.3 7.3 11 -144.8 8.2 11 3.9% 0.28 [-0.15, 1.94] 2019 Subtotal (95% C1) 107 70 70 77 77% 0.23 [-0.04, 0.50] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 ( $P = 0.48$ ); $I2 = 0\%$ Test for overall effect: Z = 1.68 ( $P = 0.09$ ) 12.4 CB Kamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtotal (95% C1) 28 28 28 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 ( $P = 0.58$ ); $I2 = 0\%$ Test for overall effect: Z = 1.68 ( $P = 0.09$ ) Total (95% C1) 28 28 28 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ), $I2 = 0\%$ Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ), $I2 = 0\%$ Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (B) Selective reporting (hzero) (D) Blinding of outcome data (attrition bias) (C) Selective reporting bias)	Kamali, Saadi et al. 2019	3,204	961	12	2,662	763	12	4.1%	0.60 [-0.22, 1.42]	2019	+	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.70, df = 2 (P = 0.70); I <sup>2</sup> = 0% Test for overall effect: Z = 1.56 (P = 0.12) <b>1.2.3 PFC</b> Holgado et al. 2019 234 35.5 36 234 41.4 36 12.9% 0.00 [-0.46, 0.46] 2019 Pollastri et al. 2020 -1,212 52 8 -1,228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 Grosprete et al. 2021 108.93 11 18 107.63 12 18 6.5% 0.11 [-0.54, 0.76] 2021 Grosprete et al. 2022 -25.93 1.32 15 -27.41 1.73 15 4.8% 0.94 [0.18, 1.70] 2022 Subtotal (95% C1) -14.3 7.3 11 -14.4.8 8.2 11 3.9% 0.19 [-0.65, 1.02] 2022 Subtotal (95% C1) -14.3 7.3 11 -14.4.8 8.2 11 3.9% 0.39 [-0.04, 0.50] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 (P = 0.48); I <sup>2</sup> = 0% Test for overall effect: Z = 1.68 (P = 0.09) <b>1.2.4 CB</b> Canali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtotal (95% C1) - 8 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtotal (95% C1) - 8 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtotal (95% C1) - 8 8 2.5% 0.89 [-0.15, 1.94] -0.05 Test for overall effect: Z = 1.68 (P = 0.09) <b>1.2.4 CB</b> Canali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtotal (95% C1) - 8 8 2.5% 0.89 [-0.15, 1.94] -0.05 Test for overall effect: Z = 1.68 (P = 0.09) <b>1.2.4 CB</b> Canali, Nami et al. 2019 90.25 0.7 8 88.25 0.88 [-0.05, 1.94] -0.05 <b>1.2.4 CB</b> Canali, Nami et al. 2019 90.25 0.7 8 88.25 0.89 [-0.15, 1.94] -0.05 Bit deterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); I <sup>2</sup> = 0% Test for overall effect: Z = 1.68 (P = 0.09) Total (95% C1) - 2 88 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), I <sup>2</sup> = 0% Test for overall effect: Z = 1.68 (P = 0.09) Di Binding of outcome assessment (detection bias) B) Allocation concealment (selection bias) B) Allocation concealment (selection bias) D) Binding of outcome assessment (detection bias) E) Incomplete outcome data (attrition bias) E) Incomplete outcome data (attrition bias) F) Selective reporting (hereoriting bias) D) Binding of outcome data (attrition bias) F) Selectiv		693.5	43.5		689	42				2021		<b>~~~</b>
L2.3 PFC ioigado et al. 2019 234 35.5 36 234 41.4 36 12.9% 0.00 [-0.46, 0.46] 2019 iolastin et al. 2020 -1,212 52 8 -1,228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 icortes et al. 2021 108.93 11 118 107.63 12 18 6.5% 0.11 [-0.54, 0.76] 2021 icortes et al. 2022 55 8.3 19 52.6 7.1 19 6.7% 0.30 [-0.34, 0.94] 2022 ilkooharf Salehi et al. 2022 -25.93 1.32 15 -27.41 1.73 15 4.8% 0.94 [0.18, 1.70] 2022 ilkooharf Salehi et al. 2022 -143.3 7.3 11 -144.8 8.2 11 3.9% 0.91 [-0.65, 1.02] 2022 ilkotharf (95% CI) 107 107 37.7% 0.23 [-0.04, 0.50] teterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 ( $P = 0.48$ ); $l^2 = 0\%$ test for overall effect: Z = 1.68 ( $P = 0.09$ ) L2.4 CB Gamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] ieterogeneity: Not applicable Test for overall effect: Z = 1.68 ( $P = 0.09$ ) L2.4 CB Gamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] ieterogeneity: Not applicable Test for overall effect: Z = 1.68 ( $P = 0.09$ ) L2.4 CB Gamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] ieterogeneity: Not applicable Test for overall effect: Z = 1.68 ( $P = 0.09$ ) L2.4 CB Gamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] ieterogeneity: Not applicable Test for overall effect: Z = 1.68 ( $P = 0.0002$ ) Test for overall effect: Z = 1.68 ( $P = 0.0002$ ) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ), $l^2 = 0\%$ test for overall effect: Z = 3.68 ( $P = 0.0002$ ) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ), $l^2 = 0\%$ test for overall effect: Z = 3.68 ( $P = 0.0002$ ) Test for overall effect: Z = 1.68 ( $P = 0.0002$ ) Test for overall effect: Z = 1.65, df = 3 ( $P = 0.65$ ), $l^2 = 0\%$ test for overall effect: Z = 1.68 ( $P = 0.0002$ ) Test for overall effect: Z = 1.68 ( $P = 0.0002$ ) Test for bala legend A) Random sequence generation (selection blas) B) Allocation concealment (selection blas) C) Blinding of outcome assessment (detection blas) E) Incomplete outcome data (attrition bl	Heterogeneity: Tau <sup>2</sup> = 0.00; C		lf = 2 (P		); I <sup>2</sup> = 09	6	52	11.1%	0.40 [-0.10, 0.89]			
Holgado et al. 2019 234 35.5 36 234 41.4 36 12.9% 0.00 [-0.46, 0.46] 2019 Pollastri et al. 2020 -1,212 52 8 -1,228 56 8 2.8% 0.28 [-0.71, 1.27] 2020 Forsopretre et al. 2021 108.93 11 18 107.63 12 18 6.5% 0.11 [-0.54, 0.76] 2021 Fortes et al. 2022 55 8.3 19 52.6 7.1 19 6.7% 0.30 [-0.34, 0.94] 2022 Vikooharf Salehi et al. 2022 -143.3 7.3 11 -144.8 8.2 11 3.9% 0.94 [0.18, 1.70] 2022 Subtotal (95% CI) 107 107 37.7% 0.23 [-0.04, 0.50] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 ( $P = 0.48$ ); 1 <sup>2</sup> = 0% Test for overall effect: Z = 1.68 ( $P = 0.09$ ) <b>1.2.4 CB</b> (amail, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtotal (95% CI) 8 8 8 2.5% 0.89 [-0.15, 1.94] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 ( $P = 0.58$ ); 1 <sup>2</sup> = 0% Test for overall effect: Z = 3.68 ( $P = 0.0002$ ) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ), 1 <sup>2</sup> = 0% Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ), 1 <sup>2</sup> = 0% Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ), 1 <sup>2</sup> = 0% Test for overall effect: Z = 3.68 ( $P = 0.0002$ ) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ), 1 <sup>2</sup> = 0% Test for overall effect: Z = 3.68 ( $P = 0.0002$ ) Test for overall effect: Z = 3.68 ( $P = 0.0002$ ) Test for overall effect: Z = 3.68 ( $P = 0.0002$ ) Test for overall effect: Z = 3.68 ( $P = 0.0002$ ) Test for overall effect: S = 3.68 ( $P = 0.0002$ ) Test for overall effect: S = 1.65, df = 3 ( $P = 0.65$ ), 1 <sup>2</sup> = 0% Test for overall effect: S = 3.68 ( $P = 0.0002$ ) Test for overall effect: S = 3.68 ( $P = 0.0002$ ) Test for overall effect: S = 3.68 ( $P = 0.0002$ ) Test for overall effect: S = 1.65, df = 3 ( $P = 0.65$ ), 1 <sup>2</sup> = 0% Test for overall effect: S = 0.0002 + 0.0002 Test for overall effect: S = 0.0002 + 0.0002 Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ), 1 <sup>2</sup> = 0% Test for overall effect: S = 0.0002 + 0.0002 Test for overall effect: S = 0.0002 + 0.0002 + 0.0002 + 0.0002 + 0.0002 + 0.0002 + 0.0002 + 0.0002		0(1 = 0.12)										
$ \frac{1}{2} 1$												
Crosprete et al. 2021 108.93 11 18 107.63 12 18 6.5% 0.11 [ $-0.54, 0.76$ ] 2021 Fortes et al. 2022 55 8.3 19 52.6 7.1 19 6.7% 0.30 [ $-0.34, 0.94$ ] 2022 Vikooharf Satehi et al. 2022 - 25.9 1.32 15 - 27.41 1.73 15 4.8% 0.94 [ $0.18, 1.70$ ] 2022 Callo et al. 2022143.3 7.3 11 - 144.8 8.2 11 3.9% 0.19 [ $-0.65, 1.02$ ] 2022 Subtotal (95% CI) 107 107 37.7% 0.23 [ $-0.04, 0.50$ ] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 (P = 0.48); i <sup>2</sup> = 0% Test for overall effect: Z = 1.68 (P = 0.09) L2.4 CB Camali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [ $-0.15, 1.94$ ] 2019 Automation of the second se												
Fortes et al. 2022 55 8.3 19 52.6 7.1 19 6.7% 0.30 [-0.34, 0.94] 2022 viktooharf Salehi et al. 2022 -25.93 1.32 15 -27.41 1.73 15 4.8% 0.94 [0.18, 1.70] 2022 Subtotal (95% CI) 107 107 37.7% 0.23 [-0.04, 0.50] Vieterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0% Test for overall effect: Z = 1.68 (P = 0.09) L.2.4 CB Camali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Vibtotal (95% CI) 8 8 2.5% 0.89 [-0.15, 1.94] Vieterogeneity: Not applicable Test for overall effect: Z = 1.68 (P = 0.09) Fotal (95% CI) 288 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: Z = 3.68 (P = 0.002) Test for overall effect: Z = 3.68 (P = 0.002) Test for subgroup differences: Chi <sup>2</sup> = 1.85, df = 3 (P = 0.65), l <sup>2</sup> = 0% Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Test for overall effect: Z = 3.68 (P = 0.002) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Test for overall effect: Z = 3.68 (P = 0.002) Test for overall effect: Z = 3.68 (P = 0.002) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% B) Allocation concealment (selection bias) B) Allocation concealment (selection bias) B) Allocation concealment (selection bias) B) Allocation concealment (selection bias) B) Allocation concealment (detection bias) E) Incomplete outcome data (attrition bias) E) Incomplete outcome data (attrition bias) E) Incomplete reporting (reporting bias)							-					
Nikooharf Salehi et al. 2022 $-25.93$ 1.32 15 $-27.41$ 1.73 15 4.8% 0.94 [0.18, 1.70] 2022 Gallo et al. 2022 $-143.3$ 7.3 11 $-144.8$ 8.2 11 3.9% 0.19 [-0.65, 1.02] 2022 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0% Test for overall effect: Z = 1.68 (P = 0.09) <b>1.2.4 CB</b> Kamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtotal (95% CI) 8 2.5% 0.89 [-0.15, 1.94] Heterogeneity: Not applicable Test for overall effect: Z = 1.68 (P = 0.09) <b>Total (95% CI)</b> 288 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: Z = 3.68 (P = 0.009) <b>Total (95% CI)</b> 288 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Six of bial segend A) Random sequence generation (selection bias) B) Allocation comealment (selection bias) B) Allocation comealment (selection bias) (D) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) E) Incomplete outcome data (attrittion bias) (E) Incomplete outcome data (attrittion bias) (F) Selective reporting (reporting bias)												
Gallo et al. 2022 $-143.3$ 7.3 $11$ $-144.8$ $8.2$ $11$ $3.9\%$ $0.19 [-0.65, 1.02]$ $2022$ Subtotal (95% CI) $107$ $107$ $37.7\%$ $0.23 [-0.04, 0.50]$ $0202 [-0.04, 0.50]$ L2.4 CB       (amail, Nami et al. 2019) $90.25$ $2.7$ $8$ $88.25$ $1.3$ $8$ $2.5\%$ $0.89 [-0.15, 1.94]$ $2019$ Heterogeneity: Not applicable       8 $2.5\%$ $0.89 [-0.15, 1.94]$ $2019$ rest for overall effect: Z = $1.68$ (P = 0.09)       8 $2.5\%$ $0.89 [-0.15, 1.94]$ $2019$ Total (95% CI)       288       288 $100.0\%$ $0.31 [0.15, 0.48]$ $-2$ $-1$ $0.12 - 1$											<u>+</u>	
Subtotal (95% CI) 107 107 37.7% 0.23 [-0.04, 0.50] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0% Test for overall effect: Z = 1.68 (P = 0.09) L.2.4 CB (armali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtotal (95% CI) 8 8 2.5% 0.89 [-0.15, 1.94] Heterogeneity: Not applicable Test for overall effect: Z = 1.68 (P = 0.09) Total (95% CI) 288 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: Z = 3.68 (P = 0.0002) Test for overall effect: Z = 3.68 (P = 0.0002) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Sixk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (F) Selective reporting (reporting bias)												4446444
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 4.47, df = 5 (P = 0.48); l <sup>2</sup> = 0% Test for overall effect: Z = 1.68 (P = 0.09) <b>1.2.4 CB</b> (camali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 (camali, Source of the experiment of the experimen		-143.3	7.3		-144.8	8.2				2022		<b>444444</b> 4
Test for overall effect: $Z = 1.68 (P = 0.09)$ <b>1.2.4 CB</b> Kamali, Nami et al. 2019 90.25 2.7 8 88.25 1.3 8 2.5% 0.89 [-0.15, 1.94] 2019 Subtotal (95% CI) 8 8 2.5% 0.89 [-0.15, 1.94] Heterogeneity: Not applicable Test for overall effect: $Z = 1.68 (P = 0.09)$ Total (95% CI) 288 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: $Z = 3.68 (P = 0.0002)$ Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting liga)		$hi^2 = 4.47$ d	f = 5 (P		$1^2 = 0^9$	6	107	57.770	0.25 [-0.04, 0.50]			
Kamali, Nami et al. 2019 $90.25$ $2.7$ $8$ $82.5\%$ $0.89$ [-0.15, 1.94] $2019$ Subtotal (95% CI) $8$ $2.5\%$ $0.89$ [-0.15, 1.94] $2019$ Heterogeneity: Not applicable       Test for overall effect: $Z = 1.68$ ( $P = 0.09$ ) $7026$ $7026$ $7026$ Total (95% CI) $288$ $288$ $100.0\%$ $0.31$ [0.15, 0.48] $-2$ $-1$ $0$ Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 ( $P = 0.58$ ); $I2 = 0\%$ $726$ $-2$ $-1$ $0$ $1$ $2$ Fest for overall effect: $Z = 3.68$ ( $P = 0.0002$ )       Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 ( $P = 0.65$ ), $I2 = 0\%$ $7266$ $7266$ $7266$				- 0.10	,, i = 0,							
Subtotal (95% Cl) 8 8 2.5% 0.89 [-0.15, 1.94] Heterogeneity: Not applicable Total (95% Cl) 288 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chl <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: Z = 3.68 (P = 0.0002) Test for subgroup differences: Chl <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Six of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (E) Incomplete outcome data (attritton bias) (F) Selective reporting (reporting bias)	1.2.4 CB											
Test for overall effect: $Z = 1.68 (P = 0.09)$ Total (95% CI) 288 288 100.0% 0.31 [0.15, 0.48] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: $Z = 3.68 (P = 0.0002)$ Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (D) Blinding of outcome data (attrition bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)		90.25	2.7		88.25	1.3				2019		9999999
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: Z = 3.68 (P = 0.0002) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (D) Blinding of outcome data (attrition bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)												
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 18.14, df = 20 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: Z = 3.68 (P = 0.0002) Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (D) Blinding of outcome data (attrition bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)	Total (95% CI)			288			288	100.0%	0.31 [0.15, 0.48]		•	
Test for overall effect: Z = 3.68 (P = 0.0002) Test for subgroup differences: Ch <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)		$hi^2 = 18.14$	df = 20		58) $l^2 =$	0%		/•		-		_
Test for subgroup differences: Chi <sup>2</sup> = 1.65, df = 3 (P = 0.65), l <sup>2</sup> = 0% <u>Risk of bias legend</u> (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)				(i = 0.	50), 1 =	070						
Risk of bias legend         A) Random sequence generation (selection bias)         B) Allocation concealment (selection bias)         C) Blinding of participants and personnel (performance bias)         D) Blinding of outcome assessment (detection bias)         E) Incomplete outcome data (attrition bias)         F) Selective reporting (reporting bias)				(P = 0)	65), $l^2 =$	0%					Favours Sham Favours tDCS	
A) Random sequence generation (selection bias) B) Allocation concealment (selection bias) C) Blinding of participants and personnel (performance bias) D) Blinding of outcome assessment (detection bias) E) Incomplete outcome data (attrition bias) F) Selective reporting (reporting bias)		1.05	, ai – J	· – ··		0/0						
B) Allocation concealment (selection bias) C) Blinding of participants and personnel (performance bias) D) Blinding of outcome assessment (detection bias) E) Incomplete outcome data (attrition bias) F) Selective reporting (reporting bias)		ion (selection	n hias)									
(C) Blinding of participants and personnel (performance bias) D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) F) Selective reporting (reporting bias)			i Dias)									
(D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)			nerforn	nance b	ias)							
(E) Incomp <sup>1</sup> ete outcome data (attrition bias) (F) Selective reporting (reporting bias)					1437							
F) Selective reporting (reporting bias)												
			/									
		ing blus)										
	ay other bias											

Fig. 3. Forest plot showing standardized mean difference (SMD) for comparing sport-specific performance changes in athletes between anodal tDCS and sham. Studies were clustered in subgroups according to the cortical target area of tDCS, i.e., motor cortex (M1), temporal cortex (TC), prefrontal cortex (PFC), and cerebellum (CB).




Fig. 4. Funnel plot of studies included in the quantitative meta-analysis divided into subgroups depending on the brain target of tDCS. Effect sizes are scattered symmetrically and all but one [54] lie within the funnel.

and within the visuomotor skill performance domain. No further significant subgroup effects were found. All results and their implications are discussed below. To contextualize the observed effect of tDCS on sport-specific performance in athletes, the variability of the respective studies must be taken into account. In principle, there is no consensus

	tD	CS		9	ham			Std. Mean Difference		Std. Mean Difference	<b>Risk of Bias</b>	
Study or Subgroup	Mean		Total	Mean	SD	Total		IV, Random, 95% CI	Year	IV, Random, 95% CI	ABCDEFG	
1.4.1 Endurance												
Okano et al. 2015	313.2	29.9	10	301	19.8	10	3.9%	0.46 [-0.43, 1.35]	2015		<b>GGGGGGG</b>	
Holgado et al. 2019	234	35.5	36	234	41.4	36	14.4%	0.00 [-0.46, 0.46]		_ <b>_</b>	444444	
Valenzuela et al. 2019	596	39	8	599	38	8	3.2%	-0.07 [-1.05, 0.91]			<b>44444</b>	
Pollastri et al. 2020	-1,212	52	8	-1,228	56	8	3.2%	0.28 [-0.71, 1.27]			GGGGGGG	
da Silva Machado et al. 2021	827.8	278.7	12	794.3	271.2	12	4.8%	0.12 [-0.68, 0.92]				
Penna et al. 2021	693.5	43.5	10	689	42	10	4.0%	0.10 [-0.78, 0.98]			<b>444</b> ? <b>44</b>	
Fortes et al. 2022	55	8.3	19	52.6	7.1	19	7.5%	0.30 [-0.34, 0.94]	2022	+	9999999	
Gallo et al. 2022	-143.3	7.3	11	-144.8	8.2	11	4.4%	0.19 [-0.65, 1.02]				
Liang et al. 2022	-1,228.65	34.31	8	-1,237	33.03	8	3.2%	0.23 [-0.75, 1.22]	2022		6666666	
Nikooharf Salehi et al. 2022 Subtotal (95% CI)	-25.93	1.32	15 137	-27.41	1.73	15 137	5.3% 54.0%	0.94 [0.18, 1.70] 0.23 [-0.01, 0.47]		<b>→</b>	999 <b>9</b> 999	
Heterogeneity: $Tau^2 = 0.00$ ; C Test for overall effect: $Z = 1.8$		f = 9 (P	= 0.82	2); $I^2 = 09$	6							
1.4.2 Strength												
Kamali, Saadi et al. 2019	3,204	961	12	2,662	763	12	4.6%	0.60 [-0.22, 1.42]	2019	+	6666666	
Fortes et al. 2021	88.7	7	12	86.7	7	12	4.8%	0.28 [-0.53, 1.08]	2021		<b></b>	
Subtotal (95% CI)			24			24	9.3%	0.44 [-0.14, 1.01]				
Heterogeneity: $Tau^2 = 0.00$ ; Chi <sup>2</sup> = 0.31, df = 1 (P = 0.58); l <sup>2</sup> = 0% Test for overall effect: Z = 1.49 (P = 0.14)												
1.4.3 Visuomotor Skill												
Mesquita et al. 2019	93.1	5.2	19	94.6	6.5	19	7.6%	-0.25 [-0.89, 0.39]			<b></b>	
Kamali, Nami et al. 2019	90.25	2.7	8	88.25	1.3	8	2.8%	0.89 [-0.15, 1.94]		<u> </u>	<b>44444</b> 4	
Mesquita et al. 2020	47.9	7.9	12	46.8	8.1	12	4.8%	0.13 [-0.67, 0.93]			<b></b>	
Grospretre et al. 2021	111.33	12		107.63	12	18	7.1%	0.30 [-0.36, 0.96]		+	<b></b>	
Kamali et al. 2021	-450	40		-481.1	43.5	14	5.2%	0.72 [-0.05, 1.49]			<b></b>	
Chen et al. 2021	0.483		13		0.047	13	5.1%	0.43 [-0.34, 1.21]		+	<b></b>	
Park et al. 2022	-2.48	1.21	13	-4.33	1.41	13	4.1%	1.36 [0.50, 2.23]	2022			
Subtotal (95% CI)			97			97	36.7%	0.45 [0.06, 0.85]		-		
Heterogeneity: Tau <sup>2</sup> = 0.12; Chi <sup>2</sup> = 10.76, df = 6 (P = 0.10); l <sup>2</sup> = 44% Test for overall effect: Z = 2.26 (P = 0.02)												
Total (95% CI)			258			258	100.0%	0.31 [0.14, 0.49]		•		
Heterogeneity: $Tau^2 = 0.00$ ; C			(P = 0	.50); I <sup>2</sup> =	0%						_	
Test for overall effect: $Z = 3.5$			<i>(</i> <b>D O</b>	F (2) 12	00/					Favours Sham Favours tDCS		
Test for subgroup differences	$: Chi^{*} = 1.16,$	df = 2	(P = 0.	.56), 1° =	0%							
Risk of bias legend												
(A) Random sequence generat		i bias)										
(B) Allocation concealment (se												
(C) Blinding of participants and				ias)								
(D) Blinding of outcome asses			s)									
(E) Incomplete outcome data (												
(F) Selective reporting (reporti	ng blas)											
(G) Other bias												

**Fig. 5. Forest plot showing standardized mean difference (SMD) for comparing sport-specific performance changes in athletes between anodal tDCS and sham.** Studies were clustered in subgroups depending on the most prominent performance indicator in each respective sport studied (e.g., cycling – endurance; bodybuilding – strength; pistol-shooting – visuomotor skill).

concerning the mode of action of tDCS as a function of specific stimulation sites. However, certain areas of the brain are known to play a role in the execution and control of athletic performance such as the primary motor cortex (M1), temporal cortex (TC), prefrontal cortex (PFC), and the cerebellum (CB). In healthy populations, anodal tDCS over M1 has been shown to enhance muscle strength in some studies [22,55,56], while others fail to replicate such effects [57,58]. This observed discrepancy may be explained by different tDCS protocols, exercises with different target muscle groups, and participants studied [58]. Similarly, mixed results exist concerning tDCS effects on endurance [59-61]. Our results corroborate this heterogeneity for sport-specific performance in athletes. Among the 11 included studies that stimulated M1, six showed performance-enhancing effects [3,41,44,48,50,54], whereas the remaining five studies failed to demonstrate any behavioral effects [24,40,42,51,52]. On a functional level, anodal tDCS over M1 has been shown to increase the excitability of M1 [4], which improves the neural drive to the working muscles [62]. An upregulation of neural output can lead to improvements in physical performance, especially in the strength domain, through enhanced utilization of neuromuscular capacities. This mechanism may constitute a factor driving the observed increases in strength measures as a result of anodal tDCS over M1 [41,48]. Furthermore, a prolongation of the onset of so-called central fatigue by M1 stimulation is also conceivable [32]. Reduced or ceased firing of motor units contributes to the loss of muscle function associated with central fatigue [63]. This process can be counteracted by tDCS via a delay of the motor slowing effect, i.e., a reduction in movement speed during fast repetitive movements [28]. A similar effect was observed in one of the studies included in our meta-analysis. Chen et al. examined the repeated-sprint ability and observed an improvement following anodal tDCS over M1 [50]. Another aspect of performance that is potentially mediated through M1 stimulation is pain tolerance. Previous research demonstrated that M1 stimulation can increase pain perception thresholds in healthy individuals [64]. It has been suggested that individuals with better pain tolerance are more successful in their sport [65]. This is supported by a study of elite athletes showing that, compared to nonathletes, elite athletes had higher pain tolerance, higher heat pain thresholds, and lower perceived pain intensity with thermal stimulation [66]. In addition, exercise-induced pain tolerance has been found to be an important factor influencing endurance exercise performance [67]. Given that fatigue during prolonged exercise is related to lower corticospinal excitability as well as decreasing pain tolerance [63,68], M1 stimulation may also enhance athletic performance due to an attenuation of exercise-induced pain.

Athletic performance necessitates the adaptation of autonomic physiology to external demands. The central autonomic network ensures such adaptations [69]. This network governs the autonomic nervous system through the integration of higher cortical centers to adapt the system to specific demands (cortical component) [70], while also comprising sympathetic and parasympathetic sections within the brainstem involved in monitoring the physiological status quo via baro- and chemoreceptor afferents (subcortical component) [69]. Essential parts of this network include the temporal cortex (TC) and the insular cortex (IC). For instance, the TC represents a higher-order control of cardiac autonomic functions [71], whereas the IC acts as a central interface between cortical and subcortical components of the central autonomic network [69]. Two studies included in our analysis stimulated TC [39,53], while another study used a dual stimulation setup of M1 and TC [41]. In a seminal study, Okano et al. demonstrated a positive effect of anodal tDCS over TC on performance in a maximal incremental exercise test on a bicycle ergometer [39]. Notably, the authors showed that the performance enhancement was due to a delay in vagal

withdrawal, suggesting a potential link between TC and control of autonomic cardiac functions, and also their susceptibility to alteration by tDCS. Vagal withdrawal describes a reduction in the activity of the vagus nerve and, in the field of exercise physiology, derives from the analysis of the standard deviation of instantaneous beat-to-beat interval variability of the heartbeat [39]. Following the results of Okano et al. [39]. Kamali et al. also found positive tDCS-induced effects on endurance and strength performance of bodybuilders following dual-stimulation of M1 and TC [41]. Again, these results were associated with vagal withdrawal, supporting the previous findings. Another study failed to observe differences in swimming performance following TC stimulation [53]. However, autonomic cardiac functions were not monitored, which complicates potential explanations concerning the absence of an effect. For this purpose, future studies aiming to stimulate TC should always monitor autonomic cardiac functions to be able to draw conclusions on the origin of potential performance enhancements.

Another area involved in exercise regulation is the prefrontal cortex (PFC). Functional roles of prefrontal subdivisions such as dorsolateral prefrontal cortex (dIPFC) and orbital prefrontal cortex (oPFC) extend from cognitive control of motor behavior [72] to the disengagement of motor activity [73], and fatigue [74]. Six studies included in this meta-analysis stimulated the PFC [3,23,45-47,49]. Given the inhibitory control of the PFC during motor activity, a common rationale of studies aiming to employ PFC stimulation is based on the assumption that an upregulation of PFC excitability leads to a reduction in effort for inhibitory control during motor activity. In this sense, the perceived effort during exercise would be reduced and the termination of exercise would be postponed [46]. Evidence for this can be found in studies demonstrating that sensory signals relating to the perception of effort are processed by areas functionally associated with the PFC, such as the supplementary motor area (SMA), premotor cortex (PMC), and M1 [75]. None of the included studies that examined perceived exertion found any modulatory effects between PFC stimulation and sham [23,45,46]. However, in all three studies, motor performance also increased. Hence, this finding might indicate an improved inhibitory control during exercise after anodal PFC stimulation, as inhibitory control moderated by prefrontal areas may contribute to the overall perception of effort during exercise [75]. tDCS may have reduced the cognitive effort needed to exert inhibitory control, allowing for higher levels of performance with the same perceived effort [46]. Another notable aspect of PFC functioning is the fact, that the ability to maintain PFC oxygenation at high exercise intensity is related to better endurance performance [76]. Moreover, PFC oxygenation decreases before the onset of fatigue [77], highlighting the importance of the PFC in the cognitive regulation of motor activity. Crucially, a direct link between anodal tDCS and an increase in cerebral, or rather prefrontal, oxygenation remains to be clearly established. However, effects of anodal tDCS on cerebral oxygenation have been demonstrated in mice, but only as a result of repetitive tDCS in a longitudinal design [78]. The effects of anodal tDCS on cerebral oxygenation in humans are currently widely debated [79]. While there are indirect indicators of tDCS-induced increases in prefrontal oxygenation [80], a causal relationship has not yet been demonstrated. With the exception of one study [23], all other studies that stimulated PFC showed an increase in motor performance in the endurance domain. Although no definitive conclusions can be drawn, it is, therefore, tempting to speculate that anodal stimulation of the PFC may delay the termination of motor activity by increasing the ability of the PFC to temporarily disregard effort-related cues and maintain a constant neural motor drive.

Finally, another brain region that plays an essential role in motor control is the CB. One aspect of cerebellar motor control relates to the so-called forward model [81]. Specifically, this model outlines the idea that the cerebellum receives a copy of the motor command and computes the sensory consequences of that command through input from the periphery [82]. Thus, the model provides a solution for dynamic adaptation of motor commands based on sensory consequences [83]. It follows that cerebellar tDCS is predominantly employed with the goal of reducing errors during motor tasks. Previous studies observed a reduction in movement errors in various tasks, with improvements mainly attributed to postural adjustments resulting from cerebellar tDCS [84,85]. In the sole study included within the present meta-analysis, the shooting accuracy of pistol shooters was increased by anodal stimulation of the cerebellum [43]. The authors attributed this to rapid postural adaptations that allowed the shooters to reduce physiological tremor. Since postural adjustments are a necessary foundation for athletic performance, future studies should examine the efficacy of cerebellar tDCS on sport-specific performance. The limited number of studies on cerebellar tDCS and performance enhancement highlights the potential to examine the efficacy of cerebellar tDCS in this area in the future.

In summary, the following observations may be noted. Of 19 included studies, 10 studies investigated effects in the endurance domain. Five of these studies found an increase in specific endurance performance (PFC (n = 4); TC (n = 1)) while five did not demonstrate such effects (PFC (n = 1); M1 (n = 3); TC (n = 1)). Two studies examined anodal tDCS effects on sport-specific strength performance and demonstrated improved performance in training volume at fixed load levels (M1 (n = 2)). The remaining 7 studies examined potential increases in visuomotor skill-dominated sports. Five studies were able to demonstrate positive anodal tDCS effects (M1 (n = 4); CB (n = 1)) whereas two studies did not observe such effects (M1 (n = 2)). Based on subgroup analyses, M1 appears to be a promising target to enhance sport-specific performance. Although some further trends can be observed (e.g., the tendency that anodal stimulation of the PFC, with the exception of one study, leads to an increase in sport-specific endurance performance in athletes), no definitive insights into the specificity of tDCS in the context of sport-specific performance enhancement in athletes can be stated.

### 4.1. Limitations and outlook

Compared to sham stimulation, anodal tDCS can induce performance-enhancing effects. This has been demonstrated in non-athletes, recreationally active individuals, and even in highlevel athletes. Despite moderate effects for M1 stimulation and within the visuomotor performance domain, we found no other differences in the efficacy of tDCS, either with respect to the site of stimulation or between different physical domains. These results might be related to the heterogeneity of the implemented stimulation protocols, especially in terms of current density and stimulation duration. Nevertheless, the present findings of this systematic review and meta-analysis provide a comprehensive overview of already established stimulation protocols and their potential in sport-specific performance enhancement. This, in turn, can guide future studies to build upon. In addition, the lack of subgroup effects can also be attributed to insufficient statistical power. Since relatively few studies have investigated tDCS effects in athletes focusing on sport-specific performance enhancements so far, future studies should focus on this issue more thoroughly. It remains to be seen whether the trend of using tDCS for performance enhancement in competitive sports will continue in the

coming years. It is important to note that some of the studies included in this meta-analysis used bilateral stimulation. The current literature describes bilateral tDCS setups in terms of either 1) a montage of active and reference electrodes on homologous cortical areas or 2) a montage of two active electrodes and one or more distal reference electrodes. The studies in question [24,42,44–46], with the exception of one study [49], used the latter setup. Due to the multi-ioint and multi-limb nature of many sports disciplines, the question arises whether and, if so, to what extent unilateral and bilateral tDCS stimulation induce different or comparable sport-specific performance changes. It is hypothesized that a potential modulation of neural networks within and between hemispheres may lead to a facilitation of motor learning performance [86]. Previous studies have shown that, for example, interhemispheric connectivity decreases during unilateral and bilateral M1 stimulation, whereas intracortical connectivity of the ipsilateral M1 increases after bilateral stimulation compared to unilateral stimulation [87]. This relationship was further explored by a study demonstrating that bilateral stimulation of the M1 leads to increases in unilateral and bilateral grip strength compared with Sham stimulation [88]. Accordingly, it is important to consider the effects of bilateral setups to contextualize potential performance-enhancing effects in relation to underlying mechanisms. However, the studies included here that use bilateral setups are heterogeneous in their actual designs and bilateral setups, making mechanistic inferences impractical. A systematic comparison between the effects of unilateral and bilateral M1 stimulations therefore seems useful in the future to uncover mechanistic differences and thus optimize existing tDCS designs with respect to desired effects. Another limitation relates to the underrepresentation of female athletes included in this metaanalysis (approximately 20% of the total sample size), a wellknown problem in current sport and exercise research [89], that limits the generalizability of our findings. Future studies should primarily examine female populations to address this issue. A final limitation concerns the classification of the performance domains. Here, our classification was an initial attempt to categorize tDCSrelated effects on athletic performance to delineate the range of tDCS effects. However, the unambiguous assignment of each sport to one of these categories is unrealistic because performance in many sports is determined by multiple athletic subdomains to varying degrees. For this reason, we decided to use the most important performance indicator as the starting point for our categorization. For example, basketball performance involves running endurance, jumping and sprinting power. However, the crucial component of basketball performance lies in the ability to effectively incorporate these components for the purpose of successful visuomotor skill performance, i.e., the ability to score points. Therefore, we categorized basketball in the performance domain of visuomotor skill-dominated sports. In the future, it seems reasonable to design tDCS studies with realistic sportspecific conditions. This will allow for a better classification of potential performance-enhancing effects and a more precise understanding of the mechanisms of tDCS in the context of sports performance.

Based on the results of this meta-analysis concerning singlesession tDCS, it seems reasonable to suggest that multi-session tDCS might be beneficial as a stand-alone technique or as an additional priming technique during ongoing training phases of athletes in terms of performance enhancement in sport-specific tasks. Indeed, preliminary evidence for such longitudinal performance-enhancing effects through M1 tDCS has been provided in adolescent professional rowing athletes [90]. Future studies should focus on such application in the context of highperformance sport to address the question of repeated performance enhancing effects over multiple sessions in highly trained individuals.

Finally, despite its ease of use, tDCS raises some safety concerns and should only be performed by an appropriately trained and experienced person to minimize risks and potential adverse effects.

# 5. Conclusions

In conclusion, a single anodal tDCS session on cortical areas relevant to motor function can lead to performance enhancement of athletes in sport-specific tasks. Although no definitive conclusions can be drawn regarding the modes of action as a function of performance domain or stimulation site, our findings imply intriguing possibilities concerning sports performance enhancement through anodal M1 stimulation. A fundamental novelty of our approach is the concept that performance enhancement in high-level athletes must also be studied in sport-specific, naturalistic settings. Apart from ethical considerations, our results can be considered as a starting point for future research on the performance enhancement of athletes by tDCS. It remains to be seen what trend future results will reveal, but the potential of this method for sports performance enhancement does not seem to be exhausted.

#### Author contributions

PR provided the idea of the systematic review and metaanalysis. TM & RK independently performed the literature search and meta-analysis. TM, PR, SP & RK wrote the manuscript. All authors interpreted the data, contributed to the manuscript, reviewed, approved the content of the final version, and agree to be accountable for all aspects of the work. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.

# Funding

None.

#### **Declaration of competing interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

#### Acknowledgments

This work was supported by the Max-Planck-Society.

#### References

- Chang M, Büchel D, Reinecke K, Lehmann T, Baumeister J. Ecological validity in exercise neuroscience research: a systematic investigation. Eur J Neurosci 2022.
- [2] Colzato LS, Nitsche MA, Kibele A. Noninvasive brain stimulation and neural entrainment enhance athletic performance—a review. J Cognit Enhanc 2017;1(1):73–9.
- [3] Grosprêtre S, Grandperrin Y, Nicolier M, Gimenez P, Vidal C, Tio G, et al. Effect of transcranial direct current stimulation on the psychomotor, cognitive, and motor performances of power athletes. Sci Rep 2021;11(1):9731.
- [4] Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol 2000;527(Pt 3):633–9.
- [5] Hassanzahraee M, Nitsche MA, Zoghi M, Jaberzadeh S. Determination of anodal tDCS duration threshold for reversal of corticospinal excitability: an

investigation for induction of counter-regulatory mechanisms. Brain Stimul 2020;13(3):832-9.

- [6] Hassanzahraee M, Nitsche MA, Zoghi M, Jaberzadeh S. Determination of anodal tDCS intensity threshold for reversal of corticospinal excitability: an investigation for induction of counter-regulatory mechanisms. Sci Rep 2020;10(1):16108.
- [7] Batsikadze G, Moliadze V, Paulus W, Kuo MF, Nitsche MA. Partially non-linear stimulation intensity-dependent effects of direct current stimulation on motor cortex excitability in humans. J Physiol 2013;591(7):1987–2000.
- [8] Jamil A, Batsikadze G, Kuo HI, Labruna L, Hasan A, Paulus W, et al. Systematic evaluation of the impact of stimulation intensity on neuroplastic after-effects induced by transcranial direct current stimulation. J Physiol 2017;595(4): 1273–88.
- [9] Antonenko D, Grittner U, Saturnino G, Nierhaus T, Thielscher A, Flöel A. Interindividual and age-dependent variability in simulated electric fields induced by conventional transcranial electrical stimulation. Neuroimage 2021;224: 117413.
- [10] Saturnino GB, Antunes A, Thielscher A. On the importance of electrode parameters for shaping electric field patterns generated by tDCS. Neuroimage 2015;120:25–35.
- [11] Datta A, Bansal V, Diaz J, Patel J, Reato D, Bikson M. Gyri-precise head model of transcranial direct current stimulation: improved spatial focality using a ring electrode versus conventional rectangular pad. Brain Stimul 2009;2(4):201–7. 7.e1.
- [12] Wiegand A, Sommer A, Nieratschker V, Plewnia C. Improvement of cognitive control and stabilization of affect by prefrontal transcranial direct current stimulation (tDCS). Sci Rep 2019;9(1):6797.
- [13] Lee HK, Ahn SJ, Shin YM, Kang N, Cauraugh JH. Does transcranial direct current stimulation improve functional locomotion in people with Parkinson's disease? A systematic review and meta-analysis. J NeuroEng Rehabil 2019;16(1): 84.
- [14] Hu K, Chen Y, Guo F, Wang X. Effects of transcranial direct current stimulation on upper limb muscle strength and endurance in healthy individuals: a systematic review and meta-analysis. Front Physiol 2022:13.
- [15] Bornheim S, Thibaut A, Beaudart C, Maquet P, Croisier JL, Kaux JF. Evaluating the effects of tDCS in stroke patients using functional outcomes: a systematic review. Disabil Rehabil 2022;44(1):13–23.
- [16] Davis NJ. Neurodoping: brain stimulation as a performance-enhancing measure. Sports Med 2013;43(8):649–53.
- [17] Edwards DJ, Cortes M, Wortman-Jutt S, Putrino D, Bikson M, Thickbroom G, et al. Transcranial direct current stimulation and sports performance. Front Hum Neurosci 2017;11:243.
- [18] Alix-Fages C, Romero-Arenas S, Castro-Alonso M, Colomer-Poveda D, Río-Rodriguez D, Jerez-Martínez A, et al. Short-term effects of anodal transcranial direct current stimulation on endurance and maximal force production: a systematic review and meta-analysis. J Clin Med 2019;8(4):536.
- [19] Chinzara TT, Buckingham G, Harris DJ. Transcranial direct current stimulation and sporting performance: a systematic review and meta-analysis of transcranial direct current stimulation effects on physical endurance, muscular strength and visuomotor skills. Eur J Neurosci 2022;55(2):468–86.
- [20] Holgado D, Vadillo MA, Sanabria D. The effects of transcranial direct current stimulation on objective and subjective indexes of exercise performance: a systematic review and meta-analysis. Brain Stimul 2019;12(2):242–50.
- [21] Cates A, Lin R, Mayberry A, Clark R, Chao D, Taylor T, et al. Repeated sessions of transcranial direct current stimulation (tDCS) with vertical jump training improves vertical jump performance in elite athletes. Brain Stimul: Basic Transl Clin Res Neuromodulation 2019;12(2):560.
- [22] Hazime FA, da Cunha RA, Soliaman RR, Romancini ACB, Pochini AC, Ejnisman B, et al. Anodal transcranial direct current stimulation (tdcs) increases isometric strength of shoulder rotators muscles in handball players. Int J Sports Phys Ther 2017;12(3):402–7.
- [23] Holgado D, Zandonai T, Ciria LF, Zabala M, Hopker J, Sanabria D. Transcranial direct current stimulation (tDCS) over the left prefrontal cortex does not affect time-trial self-paced cycling performance: evidence from oscillatory brain activity and power output. PLoS One 2019;14(2):e0210873.
- [24] Mesquita PHC, Lage GM, Franchini E, Romano-Silva MA, Albuquerque MR. Bihemispheric anodal transcranial direct current stimulation worsens taekwondo-related performance. Hum Mov Sci 2019;66:578–86.
- [25] Lattari E, Oliveira BRR, Monteiro Junior RS, Marques Neto SR, Oliveira AJ, Maranhao Neto GA, et al. Acute effects of single dose transcranial direct current stimulation on muscle strength: a systematic review and metaanalysis. PLoS One 2018;13(12):e0209513.
- [26] Shyamali Kaushalya F, Romero-Arenas S, Garcia-Ramos A, Colomer-Poveda D, Marquez G. Acute effects of transcranial direct current stimulation on cycling and running performance. A systematic review and meta-analysis. Eur J Sport Sci 2021:1–13.
- [27] Ehsani F, Bakhtiary AH, Jaberzadeh S, Talimkhani A, Hajihasani A. Differential effects of primary motor cortex and cerebellar transcranial direct current stimulation on motor learning in healthy individuals: a randomized doubleblind sham-controlled study. Neurosci Res 2016;112:10–9.
- [28] Seidel-Marzi O, Ragert P. Anodal transcranial direct current stimulation reduces motor slowing in athletes and non-athletes. BMC Neurosci 2020;21(1): 26.
- [29] Abernethy B, Baker J, Côté J. Transfer of pattern recall skills may contribute to the development of sport expertise. Appl Cognit Psychol 2005;19(6):705–18.

#### T. Maudrich, P. Ragert, S. Perrey et al.

- [30] Rosalie SM, Müller S. Expertise facilitates the transfer of anticipation skill across domains. Q | Exp Psychol 2014;67(2):319–34.
- [31] Sherwood DE. Generalization of error detection across motor tasks by men and women. Percept Mot Skills 2008;106(2):557-72.
- [32] Machado D, Unal G, Andrade SM, Moreira A, Altimari LR, Brunoni AR, et al. Effect of transcranial direct current stimulation on exercise performance: a systematic review and meta-analysis. Brain Stimul 2019;12(3):593–605.
- [33] Pelletier SJ, Cicchetti F. Cellular and molecular mechanisms of action of transcranial direct current stimulation: evidence from in vitro and in vivo models. Int J Neuropsychopharmacol 2015;18(2).
- [34] Yamada Y, Sumiyoshi T. Neurobiological mechanisms of transcranial direct current stimulation for psychiatric disorders; neurophysiological, chemical, and anatomical considerations. Front Hum Neurosci 2021;15.
- [35] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 2021;10(1):89.
- [36] Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. second ed. 2019.
- [37] Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res 2014;14: 579.
- [38] Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions; 2019. p. 205–28.
- [39] Okano AH, Fontes EB, Montenegro RA, Farinatti Pde T, Cyrino ES, Li LM, et al. Brain stimulation modulates the autonomic nervous system, rating of perceived exertion and performance during maximal exercise. Br J Sports Med 2015;49(18):1213–8.
- [40] Valenzuela PL, Amo C, Sánchez-Martínez G, Torrontegi E, Vázquez-Carrión J, Montalvo Z, et al. Enhancement of mood but not performance in elite athletes with transcranial direct-current stimulation. Int J Sports Physiol Perform 2019;14(3):310–6.
- [41] Kamali AM, Saadi ZK, Yahyavi SS, Zarifkar A, Aligholi H, Nami M. Transcranial direct current stimulation to enhance athletic performance outcome in experienced bodybuilders. PLoS One 2019;14(8):e0220363.
- [42] Mesquita PHC, Franchini E, Romano-Silva MA, Lage GM, Albuquerque MR. Transcranial direct current stimulation: No effect on aerobic performance, heart rate, or rating of perceived exertion in a progressive taekwondo-specific test. Int J Sports Physiol Perform 2020:1–6.
- [43] Kamali AM, Nami M, Yahyavi SS, Saadi ZK, Mohammadi A. Transcranial direct current stimulation to assist experienced pistol shooters in gaining evenbetter performance scores. Cerebellum 2019;18(1):119–27.
- [44] Kamali AM, Kazemiha M, Keshtkarhesamabadi B, Daneshvari M, Zarifkar A, Chakrabarti P, et al. Simultaneous transcranial and transcutaneous spinal direct current stimulation to enhance athletic performance outcome in experienced boxers. Sci Rep 2021;11(1):19722.
- [45] Gallo G, Geda E, Codella R, Faelli E, Panascì M, Ranieri LE, et al. Effects of bilateral dorsolateral prefrontal cortex high-definition transcranial directcurrent stimulation on physiological and performance responses at severeintensity exercise domain in elite road cyclists. Int J Sports Physiol Perform 2022:1–9.
- [46] Pollastri L, Gallo G, Zucca M, Filipas L, La Torre A, Riba U, et al. Bilateral dorsolateral prefrontal cortex high-definition transcranial direct-current stimulation improves time-trial performance in elite cyclists. Int J Sports Physiol Perform 2021;16(2):224–31.
- [47] Nikooharf Salehi E, Jaydari Fard S, Jaberzadeh S, Zoghi M. Transcranial direct current stimulation reduces the negative impact of mental fatigue on swimming performance. J Mot Behav 2022;54(3):327–36.
- [48] Fortes LS, Mazini-Filho M, Lima-Júnior D, Machado DGS, Albuquerque MR, Fonseca FS, et al. Transcranial stimulation improves volume and perceived exertion but does not change power. Int J Sports Med 2021;42(7):630–7.
- [49] Fortes LS, Faro H, de Lima-Junior D, Albuquerque MR, Ferreira MEC. Noninvasive brain stimulation over the orbital prefrontal cortex maintains endurance performance in mentally fatigued swimmers. Physiol Behav 2022;250:113783.
- [50] Chen CH, Chen YC, Jiang RS, Lo LY, Wang IL, Chiu CH. Transcranial direct current stimulation decreases the decline of speed during repeated sprinting in basketball athletes. Int J Environ Res Publ Health 2021;18(13).
- [51] da Silva Machado DG, Bikson M, Datta A, Caparelli-Dáquer E, Unal G, Baptista AF, et al. Acute effect of high-definition and conventional tDCS on exercise performance and psychophysiological responses in endurance athletes: a randomized controlled trial. Sci Rep 2021;11(1):13911.
- [52] Liang Z, Zhou J, Jiao F, Gin T, Wang X, Liu Y, et al. Effect of transcranial direct current stimulation on endurance performance in elite female rowers: a pilot, single-blinded study. Brain Sci 2022;12(5):541.
- [53] Penna EM, Edson, Campos BT, Ferreira RM, Parma JO, Lage GM, et al. No effects of mental fatigue and cerebral stimulation on physical performance of master swimmers. Front Psychol 2021;12.
- [54] Park SB, Han DH, Hong J, Lee JW. Transcranial direct current stimulation of motor cortex enhances spike performances of professional female volleyball players. J Mot Behav 2022:1–13.
- [55] Tanaka S, Hanakawa T, Honda M, Watanabe K. Enhancement of pinch force in the lower leg by anodal transcranial direct current stimulation. Exp Brain Res 2009;196(3):459–65.

- [56] Vargas VZ, Baptista AF, Pereira GOC, Pochini AC, Ejnisman B, Santos MB, et al. Modulation of isometric quadriceps strength in soccer players with transcranial direct current stimulation: a crossover study. J Strength Condit Res 2018;32(5):1336–41.
- [57] Kan B, Dundas JE, Nosaka K. Effect of transcranial direct current stimulation on elbow flexor maximal voluntary isometric strength and endurance. Appl Physiol Nutr Metabol 2013;38(7):734–9.
- [58] Maeda K, Yamaguchi T, Tatemoto T, Kondo K, Otaka Y, Tanaka S. Transcranial direct current stimulation does not affect lower extremity muscle strength training in healthy individuals: a triple-blind, sham-controlled study. Front Neurosci 2017;11:179.
- [59] Abdelmoula A, Baudry S, Duchateau J. Anodal transcranial direct current stimulation enhances time to task failure of a submaximal contraction of elbow flexors without changing corticospinal excitability. Neuroscience 2016;322:94–103.
- [60] Cogiamanian F, Marceglia S, Ardolino G, Barbieri S, Priori A. Improved isometric force endurance after transcranial direct current stimulation over the human motor cortical areas. Eur J Neurosci 2007;26(1):242–9.
- [61] Williams PS, Hoffman RL, Clark BC. Preliminary evidence that anodal transcranial direct current stimulation enhances time to task failure of a sustained submaximal contraction. PLoS One 2013;8(12):e81418.
  [62] Dissanayaka T, Zoghi M, Farrell M, Egan GF, Jaberzadeh S. Does transcranial
- [62] Dissanayaka T, Zoghi M, Farrell M, Egan GF, Jaberzadeh S. Does transcranial electrical stimulation enhance corticospinal excitability of the motor cortex in healthy individuals? A systematic review and meta-analysis. Eur J Neurosci 2017;46(4):1968–90.
- [63] Taylor JL, Amann M, Duchateau J, Meeusen R, Rice CL. Neural Contributions to muscle fatigue: from the brain to the muscle and back again. Med Sci Sports Exerc 2016;48(11):2294–306.
- [64] Vaseghi B, Zoghi M, Jaberzadeh S. Does anodal transcranial direct current stimulation modulate sensory perception and pain? A meta-analysis study. Clin Neurophysiol 2014;125(9):1847–58.
- [65] Mauger AR. Fatigue is a pain-the use of novel neurophysiological techniques to understand the fatigue-pain relationship. Front Physiol 2013;4:104.
- [66] Pettersen SD, Aslaksen PM, Pettersen SA. Pain processing in elite and highlevel athletes compared to non-athletes. Front Psychol 2020;11:1908.
- [67] Astokorki AH, Mauger AR. Tolerance of exercise-induced pain at a fixed rating of perceived exertion predicts time trial cycling performance. Scand J Med Sci Sports 2017;27(3):309–17.
- [68] Gandevia SC. Spinal and supraspinal factors in human muscle fatigue. Physiol Rev 2001;81(4):1725–89.
- [69] Reisert M, Weiller C, Hosp JA. Displaying the autonomic processing network in humans a global tractography approach. Neuroimage 2021;231:117852.
- [70] Beissner F, Meissner K, Bar KJ, Napadow V. The autonomic brain: an activation likelihood estimation meta-analysis for central processing of autonomic function. J Neurosci 2013;33(25):10503–11.
- [71] Dono F, Evangelista G, Frazzini V, Vollono C, Carrarini C, Russo M, et al. Interictal heart rate variability analysis reveals lateralization of cardiac autonomic control in temporal lobe epilepsy. Front Neurol 2020;11:842.
- [72] Friedman NP, Robbins TW. The role of prefrontal cortex in cognitive control and executive function. Neuropsychopharmacology 2022;47(1):72–89.
- [73] Robertson CV, Marino FE. A role for the prefrontal cortex in exercise tolerance and termination. J Appl Physiol 1985;120(4):464–6. 2016.
- [74] Rupp T, Perrey S. Prefrontal cortex oxygenation and neuromuscular responses to exhaustive exercise. Eur J Appl Physiol 2008;102(2):153–63.
- [75] Shenhav A, Musslick S, Lieder F, Kool W, Griffiths TL, Cohen JD, et al. Toward a rational and mechanistic account of mental effort. Annu Rev Neurosci 2017;40:99–124.
- [76] Santos-Concejero J, Billaut F, Grobler L, Olivan J, Noakes TD, Tucker R. Maintained cerebral oxygenation during maximal self-paced exercise in elite Kenyan runners. J Appl Physiol 1985;118(2):156–62. 2015.
- [77] Rooks CR, Thom NJ, McCully KK, Dishman RK. Effects of incremental exercise on cerebral oxygenation measured by near-infrared spectroscopy: a systematic review. Prog Neurobiol 2010;92(2):134–50.
- [78] Bragina OA, Lara DA, Nemoto EM, Shuttleworth CW, Semyachkina-Glushkovskaya OV, Bragin DE, Increases in microvascular perfusion and tissue oxygenation via vasodilatation after anodal transcranial direct current stimulation in the healthy and traumatized mouse brain. Adv Exp Med Biol 2018;1072:27–31.
- [79] Figeys M, Zeeman M, Kim ES. Effects of transcranial direct current stimulation (tDCS) on cognitive performance and cerebral oxygen hemodynamics: a systematic review. Front Hum Neurosci 2021;15:623315.
- [80] Nelson JT, McKinley RA, Golob EJ, Warm JS, Parasuraman R. Enhancing vigilance in operators with prefrontal cortex transcranial direct current stimulation (tDCS). Neuroimage 2014;85(Pt 3):909–17.
- [81] Sokolov AA, Miall RC, Ivry RB. The cerebellum: adaptive prediction for movement and cognition. Trends Cognit Sci 2017;21(5):313–32.
- [82] Herzfeld DJ, Kojima Y, Soetedjo R, Shadmehr R. Encoding of action by the Purkinje cells of the cerebellum. Nature 2015;526(7573):439–42.
  [83] Frens MA, Donchin O. Forward models and state estimation in compensatory
- [83] Frens MA, Dorichin O. Forward models and state estimation in compensatory eye movements. Front Cell Neurosci 2009;3:13.
- [84] Galea JM, Vazquez A, Pasricha N, de Xivry JJ, Celnik P. Dissociating the roles of the cerebellum and motor cortex during adaptive learning: the motor cortex retains what the cerebellum learns. Cerebr Cortex 2011;21(8):1761–70.

T. Maudrich, P. Ragert, S. Perrey et al.

- [85] Poortvliet P, Hsieh B, Cresswell A, Au J, Meinzer M. Cerebellar transcranial direct current stimulation improves adaptive postural control. Clin Neurophysiol 2018;129(1):33–41.
- [86] Morya E, Monte-Silva K, Bikson M, Esmaeilpour Z, Biazoli Jr CE, Fonseca A, et al. Beyond the target area: an integrative view of tDCS-induced motor cortex modulation in patients and athletes. J NeuroEng Rehabil 2019;16(1): 141.
- [87] Sehm B, Kipping J, Schafer A, Villringer A, Ragert P. A comparison between uni- and bilateral tDCS effects on functional connectivity of the human motor cortex. Front Hum Neurosci 2013;7:183.
- [88] Hikosaka M, Aramaki Y. Effects of bilateral transcranial direct current stimulation on simultaneous bimanual handgrip strength. Front Hum Neurosci 2021;15:674851.
- [89] Cowley ES, Olenick AA, McNulty KL, Ross EZ. "Invisible sportswomen": the sex data gap in sport and exercise science research. Women Sport Phys Activ J 2021;29(2):146–51.
- [90] Liu X, Yang X, Hou Z, Ma M, Jiang W, Wang C, et al. Increased interhemispheric synchrony underlying the improved athletic performance of rowing athletes by transcranial direct current stimulation. Brain Imaging Behav 2019;13(5): 1324–32.